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Host cell gene expression during the course of a human adenovirus infection in synchronized primary human lung fibroblasts was analyzed using
cDNA microarrays. The slow progression of the infectious cycle in these cells allowed a detailed examination of cellular gene regulation. In total, 988
unique geneswere identified as differentially expressedmore than 2-fold. The cellular gene expression profiles closely correlated to the progression of the
infection. Based on the observed expression patterns, the deregulation of cellular genes' expression could be separated into four periods: (i) the immediate
response of the host to incoming virus; (ii) deregulation of cellular genes involved in cell cycle, growth control, and antiviral response; (iii) steady-state
regulation of cellular gene expression during viralDNA replication; (iv) targeting of cellular genes involved in intra- and extra-cellular structure at the late
phase of infection. The struggle of the virus to gain control of TGF-β and Wnt signaling, as well as the apoptotic pathways, was conspicuous.
© 2007 Elsevier Inc. All rights reserved.Keywords: Adenovirus; Microarray; Time course; Host cell gene expressionIntroduction
An important aspect of the interaction between adenovirus
and its host is the modulation of host cell gene transcription.
The immediate response of the cell to the incoming adenovirus
involves genes linked to two major cellular processes; inhibition
of cell growth and immune response (Granberg et al., 2006).
Most of these genes encode transcription factors. The response
is probably triggered by the attachment of the virus to cell
surface receptors, the entry process of the virus or its
intracellular transport along the microtubules. Several cellular
signaling pathways, such as PKA and p38/MAPK, have been
shown to be activated immediately after infection (Suomalainen
et al., 2001). To ascertain an efficient production of progeny
virus, adenovirus has to counteract the antiviral defense of the
host, as well as induce optimal conditions for viral DNA
replication by forcing the infected host cell to enter S-phase. To
this end, adenoviruses encode several regulatory proteins within
early regions 1A (E1A), E1B, E3, and E4. E1A is the first viral
gene to be transcribed and the E1A proteins are required for
transcriptional activation of all viral genes. They also act as⁎ Corresponding author. Fax: +46 18 471 4808.
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doi:10.1016/j.virol.2007.02.013promiscuous transcriptional activators or repressors of cellular
genes (Flint and Shenk, 1997). The deregulation of the cell
cycle is mainly ascribed to the ability of the E1A proteins to
bind members of the retinoblastoma tumor suppressor (pRB)
family, thereby allowing the E2F transcription factors to
activate genes required in S-phase (Bayley and Mymryk,
1994; Cobrinik, 1996). Our previous studies showed that the
virus indeed causes a significant deregulation of many E2F-
dependent cellular genes (Zhao et al., 2003). The transcription
factor E2F also serves an important function for the virus, as it is
required to obtain efficient expression from the adenovirus E2
promoter (Kovesdi et al., 1986). In addition, E1A targets the
transcriptional co-activators p300/CBP, which have been
implicated in multiple cellular processes by interacting with a
growing list of transcription factors (Arany et al., 1995;
Bannister and Kouzarides, 1995). As co-activators, p300/CBP
act as transcriptional integrators creating architectural scaffolds
for transcription complex assembly and they act also as
chromatin modifiers through their intrinsic acetyl transferase
activities (Branton and Roopchand, 2001). The ability of E1A to
bind and sequester p300/CBP is a likely explanation for
transcriptional repression by E1A, although it mainly leads to
the induction of cell proliferation (Arany et al., 1995; Bannister
and Kouzarides, 1995). Furthermore, E1A may also redirect
p300/CBP to activate specific target genes (Fax et al., 2000).
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tin-remodeling complexes (Deleu et al., 2001; Fuchs et al.,
2001; Lang and Hearing, 2003; Nikiforov et al., 2002) and the
co-repressor C-terminal Binding Protein (CtBP) (Chinnadurai,
2004; Johansson et al., 2005), offers additional possibilities for
E1A to deregulate cellular transcription. Thus, the ability of
E1A to target different cellular proteins involved in transcrip-
tional regulation creates a variety of possibilities to regulate the
cell growth controlling activities of the host.
A negative consequence of the S-phase-stimulatory activities
is that the binding of E1A to pRb and p300/CBP promotes p53
accumulation, which leads to the induction of p53-dependent
apoptosis (Debbas and White, 1993; Lowe and Ruley, 1993).
E1A can also sensitize infected cells to TNFα- and TRAIL-
induced apoptosis (Chen et al., 1987; Duerksen-Hughes et al.,
1989; Routes et al., 2000). The E1B-55K plays a major role in
counteracting the pro-apoptotic program, either by binding to
p53 and actively repressing p53-dependent transcription (Yew
et al., 1994), or by promoting the degradation of p53 through an
E4orf6-E3 ubiquitin ligase complex (Querido et al., 2001). The
E1B-19K protein is a viral Bcl-2 homologue that acts as a broad
inhibitor of mitochondria-dependent apoptosis (Farrow et al.,
1995; Han et al., 1996). Furthermore, E1B-19K was also
recently suggested to interfere directly with the activity of p53
when translocated to the mitochondria (Lomonosova et al.,
2005). In addition, E1A can also counteract its own induction of
p53 apoptosis by blocking p53 transcriptional activation
through sequestration of p300/CBP (Somasundaram and El-
Deiry, 1997).
Several immunomodulatory proteins are encoded within the
E3 transcription unit to repress the host immune response and
protect the infected host cell from immune surveillance. The
interference with the host antiviral response involves the
capacity of adenovirus E3 proteins to interrupt antigen
presentation and pro-inflammatory signaling (Wold et al.,
1994). E3-gp19K prevents exposure of viral peptides on the
cell surface by inhibiting the transport of class I major
histocompatibility complex from the ER to the plasma
membrane as well as inhibiting the loading of peptide by
tapasin (Bennett et al., 1999; Burgert et al., 1987; Wold et al.,
1999). The E3-10.4K and 14.5K (RIDα/β) complex inhibits
tumor necrosis factor alpha (TNFα) and Fas ligand-induced
cell death through internalization of the death domain
containing receptors, which are subsequently degraded in the
lysosome. In addition, the E3-10.4K/14.5K complex also
blocks the activation of NFκB by preventing NFκB from
entering the nucleus, as well as by inhibiting the activity of the
kinase complex IKK (Friedman and Horwitz, 2002). Since the
transcription factor NFκB promotes the expression of several
hundred target genes, mainly involved in the host immune
response (Ghosh et al., 1998), it is anticipated that the
inhibition of the NFκB pathway leads to deregulated
expression of many target genes. Furthermore, it has been
shown that over-expression of E3 could lead to the inhibition
of chemokine expression and subsequent secretion in response
to inflammatory stimuli (Lesokhin et al., 2002). E1A is also
important for the immunosuppressing abilities of the virus.Since the p300/CBP co-activators act on transcription factors
controlling genes involved in antiviral defense, it is con-
ceivable that this causes deregulation of these genes. It has
been shown that E1A represses NFκB activity by targeting the
p300/CBP co-activators and by inhibition of NFκB acetylation
(Jennings-Gee et al., 2006). In addition, repression of the
NFκB pathway has also been reported to occur both as a
consequence of E1A inhibition of IKK (Shao et al., 1999) and
as an undefined activity of the Rb-binding domain of E1A
(Cook et al., 2002).
After the onset of adenovirus DNA replication, viral
transcription switches from the early to the late mode.
Concurrently, cellular gene expression is also changed. Most
of the differentially expressed cellular genes are found to be
down-regulated (Granberg et al., 2005), indicating that
adenovirus employs additional strategies to redirect the cellular
synthesis machinery to virus production during the later stages
of infection. This could be due to: (i) a dramatic increase in
transcription-competent adenoviral DNA that competes for the
cellular transcription machinery and titrates cellular repressors
(Iftode and Flint, 2004); (ii) viral genes expressed during the
late phase. Through a shift in splice selection, expression of
E1A is changed from mRNAs preferentially encoding the 289R
major transcriptional activator during the early phase to
producing the shorter mRNA which encodes the E1A-243R
protein during the late phase of the infection (Chow et al.,
1979). This shorter variant of E1A mainly functions as a
transcriptional repressor through its capacity to bind p300/CBP
(Jones, 1995). The L4-100 kDa protein expressed from the
major late transcription unit also regulates viral gene expression
and shuts off cellular gene expression (Cuesta et al., 2000;
Farley et al., 2004; Hayes et al., 1990). Furthermore, the export
of cellular mRNA from the nucleus is blocked, whereas the
export of viral mRNAs is maintained. The E1B-55 kDa/E4-
34 kDa protein complex is required for this specific transport
through the nuclear membrane (Bridge and Ketner, 1990;
Corbin-Lickfett and Bridge, 2003; Sarnow et al., 1984).
It is clear from previous studies that adenoviruses have
evolved many sophisticated mechanisms by which the virus can
interact with the host to optimize its reproduction. Previously,
we have described the deregulation of cellular gene expression
during the early, 6 hours post-infection (hpi), and late phases, 10
and 20 hpi, of an adenovirus infection in HeLa cells (Granberg
et al., 2005; Zhao et al., 2003). There are several limitations in
these studies since HeLa cells were used as hosts for the virus.
HeLa cells are transformed cells, which grow rapidly and are
very difficult to synchronize. Thus, there is a risk that genes
involved in the control of cell cycle and growth might have
escaped detection. Moreover, the replication of adenovirus in
HeLa cells is extremely efficient. There is thus a narrow time
window for examination of the details of cellular gene
expression. In the present study, we have used an unbiased
approach to study perturbations of the host cell that occur
during the adenovirus replication cycle. While our previous
studies included only three time points and examination of a
limited number of cellular genes, here we present a time course
analysis of host cell gene expression during the adenovirus type
Fig. 2. Heat map visualization of differentially expressed cellular genes. Genes
sorted according to time points of expression changes larger than 2-fold. Six
groups with distinct expression profiles were identified.
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(IMR-90).
Results
Profiling of host cell gene expression during the course of an
adenovirus infection
In order to facilitate the detection of genes involved in cell
cycle and growth, the IMR-90 cells were synchronized by
contact inhibition. The cells were continually cultured for 48 h
after they had reached confluency. FACS analysis revealed
that about 95% of the cells were then in the G0/G1 phase
(data not shown). The progression of the adenovirus infection
was followed by measuring the expression of the adenovirus
early E1A gene and the cellular cyclin E1 gene (CCNE1) from
6 to 48 hpi using QRT-PCR analysis. The replication of
adenovirus DNA was also monitored. As shown in Fig. 1,
expression of E1A could be detected at 12 hpi, which then
steadily increased up to 30 hpi. CCNE1 was also found to be
expressed and reached its maximum level at 18 hpi, indicating
that infected cells were in the late G1 phase of the cell cycle.
Viral DNA replication began at 24 hpi, marking the beginning
of the late phase. The decline of adenoviral DNA level after
36 hpi was probably due to the incorporation of viral DNA
into new virus particles. A clear cytopathic effect was
observed after 40 hpi. Accordingly, a time course experiment
including eight time points from 6 to 48 hpi with 6-h intervals
was performed using microarrays, which contained 29,800
cDNA clones.
Approximately 32% of the cDNA clones gave a detectable
signal. Among them, 988 unique genes were identified to be
differentially expressed more than 2-fold in adenovirus-
infected cells as compared to uninfected cells. Broadly, these
genes fell into six groups based on their expression patterns
(Fig. 2). The first group contained 212 up-regulated genes. The
majority of these genes were activated during the early phase
of the infection (from 12 to 24 hpi), and most of them
remained at a similar level until the late stage of infection. The
second group included 124 genes that were up-regulated
during the early phase of the infection but became down-Fig. 1. Progression of adenovirus infection in IMR-90 cells. The RNA level of
E1A and CCNE1 was measured by QRT-PCR using E1A- or CCNE1-specific
primers, respectively. The adenoviral DNA replication was measured by using
E1A primers.regulated during the late stage of the infection. The third group
contained 48 genes that were up-regulated at a very late stage
of the infection. The fourth group, which was the largest one,
consisted of 377 genes, most of which were down-regulated
during the early phase and sustained until the very late stage of
infection. The fifth group comprised 211 genes, whose down-
regulation started in the late stage of infection. The sixth group
contained only 16 genes, which were transiently up-regulated
only at 12 hpi and then declined to similar levels as in
uninfected cells or lower during the late phase of infection.
The number of differentially expressed genes during the
progression of the infection is shown in Fig. 3. At the earliest
time point, 6 hpi, only 3 genes were found to be differentially
expressed. The number of differentially expressed genes
increased rapidly from 12 hpi, when expression of E1A
began, until 24 hpi when adenovirus DNA replication started.
This was followed by a period from 24 to 36 hpi when cellular
gene expression largely remained at a steady state. After the
peak of adenoviral DNA replication at 42 hpi, the number of
down-regulated cellular genes increased dramatically and more
than 70% of differentially expressed genes were down-
regulated at 48 hpi. From our data, it was apparent that the
Fig. 3. Numbers of differentially expressed cellular genes at different time points
after adenovirus infection.
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involved cell cycle, cell proliferation, antiviral response, and
cellular structure. The complete data set is included in the
supplementary material.
Cellular gene expression during the early phase of adenovirus
infection
The major events during the early phase of the infection
were the induction of S-phase and the suppression of the host
cell immune response. Seventy-one genes implicated in cell
cycle and proliferation were identified as shown in Table 1.
About two-thirds of the genes in this category were deregulated
during the early phase of infection. These genes could be
further divided into subgroups based on the cellular pathways
they perturbed. The majority of the genes involved in cell cycle
regulation were up-regulated and most of the changes occurred
between 12 and 24 hpi. Among them, Cyclin E1/2, cyclin D2,
CCNA2, CDC25A, CDK4, CKS2 and CKS1B have been
shown to be essential for the cell cycle control at the G1/S
transition. In contrast, eight genes encoding various growth
factors (VEGF, VEGFC, NRG2 and NGFB) or their interacting
protein (NAB2) and receptors (FGFR1, FGFR4 and PDGFRA)
were down-regulated.
All genes involved in the TGF-β pathway were down-
regulated except FST, and the repression was observed early
after the infection. Although the TGF-β superfamily members,
BMP2 and INHBA, and their receptors, ACVR1 and TGFBR1,
were repressed, the expression of some negative regulators of
the TGF-β pathway, such as SMURF1, SMURF2, GREM1 and
FST, was also decreased. This suggests that the regulation of the
TGF-β pathway is complicated at the gene expression level.
Most of the differentially expressed cellular genes implicated
in antiviral defense were down-regulated as shown in Table 2.
Fifty percent of them were detected during the early phase of
infection (12–24 hpi). The expression of several secreted
proinflammatory cytokines and chemokines was suppressed
during the early phase of infection. Decreasing expression of
cytokines or their related genes (LIF, IL6, and IL1R1) was
evident at 12 hpi, and the number of genes in this group
increased until 24 hpi (IL11, CCL2, CXCL12, TNFAIP3 and
TNFRSF11B). Subsequently, the expression of most of thecytokine-mediated genes, especially those implicated in the
NFκB and JNK/STAT pathways and their target genes, was
deregulated. Among the genes involved in immunodefense,
NFκB and its positive regulators (RNF25 and GPR177) were
down-regulated, whereas its negative regulator, COMMD4 was
up-regulated leading to inhibition of the NFκB pathway.
Surprisingly, NFKBIA, TNFAIP3 and NKIRAS2, which inhibit
the NFκB pathway were also found to be down-regulated,
indicating that of the shut-off of the NFκB was incomplete. All
three genes (STAT3, SOCS3 and ASB1) identified here involved
in JNK/STAT pathways were down-regulated at the very late
phase of the infection.
Deregulation of a series of genes that are involved in
apoptosis was also apparent. Several genes known to be pro-
apoptotic, including BNIP3L, HIPK2, SH3RF1, TNFRSF11B,
BAT3, NALP1, and STK4, were down-regulated. Approxi-
mately half of these genes were down-regulated during the
early phase of infection. Concordantly, expression of TRAP1,
known to be anti-apoptotic, was found to be up-regulated.
However, some genes like FAF1, PDCD5 and CRR9, which
promote apoptosis, were found to be up-regulated, and the
expression of an apoptosis suppressor, BIRC2, was down-
regulated. Thus, there seems to be an ongoing battle between
the virus and its host.
Cellular gene expression alterations from 24 to 36 hpi during
the viral DNA replication phase
Adenoviral DNA replication started at 24 hpi. Cellular gene
expression was maintained at a relatively constant level from 24
to 36 hpi (Fig. 3). The majority of the differentially expressed
genes identified at 24 hpi were sustained at 30 and 36 hpi. By
24 hpi, numerous genes involved in DNA, RNA and protein
synthesis were activated (Table 3A). Genes directly involved in
DNA replication were up-regulated already at 18 hpi (POLE,
RFC4, RFC3, POLD3, PARP1, EXO1, TK1, DHFR, RRM2
and DDX12), and most of these genes remained at a constant
level until the late phase of the infection.
A large number of the differentially expressed cellular genes
(about 100 genes) were involved in various aspects of
transcription, such as RNA synthesis, transcriptional regulation,
posttranscriptional processing. Two-thirds of these genes
encoded transcription factors (data not shown). In addition, a
group of genes involved in RNA splicing was notable. As
shown in Table 3B, most of these genes were up-regulated at
24 hpi. A few genes were down-regulated, but this occurred
very late in the infection cycle.
Deregulation of cellular genes at the very late stages of
infection
From 42 to 48 hpi, the number of down-regulated cellular
genes was significantly increased (see Fig. 3) and at 48 hpi,
seventy percent of the differentially expressed genes were
down-regulated. The most conspicuous change was the down-
regulation of a large number of genes involved in intra- and
extra-cellular structure. Concordantly, a clear change in host cell
361H. Zhao et al. / Virology 363 (2007) 357–375morphology was observed by 42 hpi as most of the cells became
rounded-up.
A broad range of genes involved in various steps of actin
filament assembly were down-regulated (Table 4A), such as (i)
the regulator of cdc42 signaling (CDC42EP3), (ii) an initiator of
actin filament nucleation (ARPC5L), (iii) linkers for actin-
membrane attachment (PPP1R9B, PXN, MSN), (iv) attachment
sites for actin filaments (CD44, ITGB4 and ITGA2), (v) actin-
associated proteins which regulate actin filament formation
(PHACTR2, LASP1, COTL1, ENAH, VASP, KLHL5), (vi) a
motor protein (MYO10) and its regulator (MRLC2), and (vii) the
actin-bundling protein (ACTN1). Apparently, the attack on the
actin filaments occurs at multiple levels.
Similarly, numerous genes involved in microtubule organi-
zation were also down-regulated. These included the micro-
tubule basic structural subunit (TUBB2C), the centrosome
structural component (CETN2), the motor proteins (KIFC3 and
DYNLL1) and their interacting protein (PAFAH1B1), as well as
several microtubule-associated proteins (MAP1B, MAP1LC3B,
BPY2IP1). In addition, numerous genes encoding proteins that
function as linkers that mediate the binding of organelles to
microtubules, such as HOOK2 and CLIPR-59 were also down-
regulated. In contrast, only three genes (TUBE1, TTL and
TBCA) were up-regulated during the later stages of the
infection.
One of the major functions of the microtubules is the transport
of membrane-enclosed organelles. Consistently, the expression of
a large number of genes involved in intracellular vesicular
trafficking was decreased (Table 4B). A notable group of down-
regulated genes comprised genes involved in regulation of
membrane vesicle transport, such as genes belonging to the Rab
family or Rab-interacting proteins (RAB7, RAB11FIP1, RA-
B6IP1, and RABGEF1), genes encoding syntaxins (STX6 and
STX1A) and sorting nexin-related proteins (SNX9, SNX12,
SNX30 and SNAG1). In addition, the down-regulation of
numerous genes involved in non-clathrin-coated (or COPI and
COPII-coated) vesicle-mediated protein transport between the
endoplasmic reticulum (ER) and the Golgi apparatus, and
between Golgi cisternae, was also significant. These included
genes involved in various steps of non-clathrin-coated vesicle
assembly, transport and fusion with the target membrane (COPB,
SEC24D, SEC31L1, ARF1, TRAPPC4, NSFL1C, VCP, GGA2
and GOLGA2).
Finally, a set of genes involved in cell junction formation and
the extra-cellular matrix were targeted during the late stage of
the infection (Table 4C). Starting from the early phase of
infection, several genes in this category were differentially
expressed, but more extensive deregulation occurred during the
very late stage of the infection when the majority of the genes
were down-regulated. The major components of the tight
junction, CLDN3 and 4, were down-regulated from 18 hpi and
the repression was sustained until the late stage of infection.
Collagens are the major proteins of the extra-cellular matrix.
We found that the expression of seven different types of
collagen (COL1A1, COL5A1, COL6A1, COL6A3, COL12A1,
COL15A1 and COL16A1) was decreased significantly. In
addition, genes encoding other fibrous proteins (LAMB2 andFN1) and glycosaminoglycans (SDC4) were also down-
regulated. Interestingly, the expression of genes encoding
matrix metalloproteases (MMP11 and MMP19) and plasmino-
gen (PLG) that degrade matrix protein were up-regulated,
whereas the expression of matrix metalloprotease inhibitors and
tissue inhibitors of metalloproteinase (TIMP2 and TIMP3) was
down-regulated. The deregulation of a large number of genes
implicated in both intra- and extra-cellular structure is likely to
play an important role for the release and spread of viral
progeny.
QRT-PCR validation of the microarray results
The results obtained by the microarray analysis were
validated by QRT-PCR. In total, 32 genes were analyzed and
the results, together with the corresponding microarray data,
were summarized in Table 5. Most of these genes were selected
because of their significant biological functions. Among the 32
genes that were analyzed, the QRT-PCR results for 28 genes
were consistent with the microarray data, although the
magnitude of the difference was generally greater when
measured by QRT-PCR. We failed to confirm the differential
expression of four genes, MDM2, CFL2, SERPINB2 and
WDR34 by QRT-PCR. In addition, QRT-PCR revealed an up-
regulation of several cellular genes, such as DKK1, TGFBR1,
TRAP1 and ELL2 during the very early phase of the infection,
which reflected the lower sensitivity of the microarray analysis.
The QRT-PCR did in fact show that the down-regulation of the
same gene was very dramatic. For instance, INHBAwas down-
regulated over 20-fold from microarray results, but it was down-
regulated over 100-fold as measured by QRT-PCR.
Studies of the TGF-β pathway at the protein level
Microarray analysis generated contradictory results regard-
ing the regulation of the TGF-β pathway, since both positive
(BMP2, INHBA, ACVR1 and TGFBR1) and negative regulators
(GREM1, SMURF1 and 2) were down-regulated at the gene
expression level. It has been shown that SMURF1 and 2 interact
with receptor-regulated SMADs to promote their degradation
(Murakami et al., 2003; Zhang et al., 2001). Thus, the down-
regulation of SMURF1 and 2 suggested that the protein levels
of the SMADs, the key players in the TGF-β signaling pathway,
should remain stable or increase during the infection. Therefore,
the expression of SMAD1, 2, 3 and 4 at the protein level was
analyzed by Western blotting. As shown in Fig. 4, the protein
level of SMAD4 was increased significantly at 18 hpi and then
remained elevated until very late in the infection, whereas
expression of SMAD2 and SMAD1/3 remained constant or
slightly increased after 18 hpi.
Discussion
Two major features characterized host cell gene expression
during an adenovirus infection. Firstly, the cellular gene
expression profile correlated with the progression of the
adenovirus infection and secondly, adenovirus targeted a limited,
Table 1
Differentially expressed genes involved in cell cycle and proliferation
Category Clone ID Symbol 6 h 12 h 18 h 24 h 30 h 36 h 42 h 48 h Name
Cell cycle 453107 CDC45L – a 2.2 b 3.6 5.9 3.7 4.0 6.4 6.0 CDC45 cell division cycle 45-like
(S. cerevisiae)
789182 PCNA c 1.3 3.5 7.4 7.3 4.5 4.7 2.4 2.6 Proliferating cell nuclear antigen
809557 MCM3 – 2.1 3.4 2.7 2.7 3.4 – 2.1 MCM3 minichromosome maintenance
deficient 3
130204 MCM4 – 2.6 3.9 4.7 3.8 4.9 4.3 4.1 MCM4 minichromosome maintenance
deficient 4
700721 MCM5 – 3.7 5.8 7.0 5.5 5.4 5.6 7.6 MCM5 minichromosome maintenance
deficient 5
855390 MCM6 – 2.1 3.2 3.1 3.3 3.3 2.8 3.5 MCM6 minichromosome maintenance
deficient 6
826273 CCNE2 – – 4.0 4.0 2.2 2.3 2.3 2.5 Cyclin E2
68950 CCNE1 c – – 2.5 2.3 – – – – Cyclin E1
809685 PA2G4 1.1 1.7 2.3 2.7 2.7 3.0 2.4 2.3 Proliferation-associated 2G4, 38 kDa
112576 BCCIP – 1.2 2.4 2.9 2.7 2.4 2.7 3.9 BRCA2 and CDKN1A interacting protein
815526 MYBL2 – – 3.7 2.9 4.9 5.2 2.4 7.5 V-myb myeloblastosis viral oncogene
homolog (avian)-like 2
773308 CCDC5 1.0 1.4 2.3 2.6 2.7 2.8 2.4 2.6 Coiled-coil domain containing 5
(spindle-associated)
204301 CDC25A – – 3.8 3.2 2.1 3.5 – – Cell division cycle 25A
204214 CDC6 – – 4.0 4.9 2.7 3.9 – – CDC6 cell division cycle 6 homolog
(S. cerevisiae)
51737 RBBP8 – – 2.1 2.2 2.4 2.2 – – Retinoblastoma binding protein 8
814270 CCNA2 – 1.5 2.4 3.1 1.9 1.3 – – Cyclin A2
296155 CDCA5 – – 3.3 4.2 – – – – Cell division cycle-associated 5
376316 WEE1 1.1 1.5 2.0 1.7 1.3 1.3 – 1.6 WEE1 homolog (S. pombe)
359119 CKS2 1.1 1.3 1.7 2.1 2.2 1.4 – 1.3 CDC28 protein kinase regulatory subunit 2
856289 CCNB2 – – 1.7 3.4 4.0 2.2 – 3.6 Cyclin B2
321708 TFDP1 1.1 1.3 1.7 2.2 2.2 2.9 2.1 2.6 Transcription factor Dp-1
842946 CDC27 1.1 1.8 2.0 2.1 1.9 2.5 2.1 1.7 Cell division cycle 27
2018976 PTTG1 1.1 1.2 1.5 2.3 3.2 2.2 2.8 4.0 Pituitary tumor-transforming 1
246304 BTG3 −1.1 −1.2 1.9 2.2 2.6 2.8 2.1 2.4 BTG family, member 3
810899 CKS1B – 1.1 1.3 1.7 2.0 2.0 1.7 2.0 CDC28 protein kinase regulatory subunit 1B
842806 CDK4 −1.0 1.2 1.6 1.8 1.8 2.3 1.4 1.3 Cyclin-dependent kinase 4
781061 CDC14B 1.1 −1.3 −2.5 −2.8 −2.5 −2.6 −3.3 −3.6 CDC14 cell division cycle 14 homolog B
(S. cerevisiae)
770888 CCNI −1.1 −1.1 −1.7 −2.1 −1.7 −1.5 −2.4 −2.6 Cyclin I
249688 CCND2 −1.2 −1.5 −1.9 −2.4 −2.1 −2.1 −2.3 −2.7 Cyclin D2
487287 RGC32 1.1 −1.4 −1.6 −1.8 −2.3 −1.8 −2.5 −2.9 Response gene to complement 32
815047 CCNL1 −1.0 −1.8 −1.5 −1.7 −2.1 −2.5 −3.0 −2.7 Cyclin L1
786048 E2F4 1.1 −1.0 −1.2 −1.3 −1.4 −1.7 −1.6 −2.2 E2F transcription factor 4, p107/p130-binding
Growth factor and
related genes
34778 VEGF c −1.7 −2.4 −2.7 −3.9 −3.6 −3.1 −4.1 −6.0 Vascular endothelial growth factor
45138 VEGFC 1.2 −1.1 −2.4 −3.1 −2.7 −2.8 −3.0 −4.1 Vascular endothelial growth factor C
1240116 NRG2 −1.1 −1.9 −3.1 −2.8 −2.8 −2.4 −2.7 −2.4 Neuregulin 2
72869 NGFB −1.1 −1.7 −2.5 −2.3 −2.8 −1.8 −1.8 −2.4 Nerve growth factor, beta polypeptide
154472 FGFR1 1.0 −1.2 −1.7 −2.2 −2.5 −2.6 −2.9 −3.4 Fibroblast growth factor receptor 1
784224 FGFR4 −1.2 1.1 1.0 −1.5 −1.2 −1.2 −2.3 −2.1 Fibroblast growth factor receptor 4
52096 PDGFRA 1.2 1.3 1.2 −1.2 −1.3 −1.4 −1.7 −2.3 Platelet-derived growth factor receptor,
alpha polypeptide
1926749 NAB2 1.3 1.3 −1.2 −1.3 −2.0 −1.6 −1.6 −2.0 NGFI-A binding protein 2 (EGR1 binding
protein 2)
WNT pathway 239256 FZD7 c 1.8 2.1 2.0 2.8 1.4 1.4 1.0 1.3 Frizzled homolog 7 (Drosophila)
206838 APC 1.0 1.4 1.6 2.5 3.7 3.2 3.2 4.8 Adenomatosis polyposis coli
294973 LRP6 1.2 1.2 1.3 1.5 1.7 2.1 1.7 1.8 Low-density lipoprotein receptor-related
protein 6
52629 CAMK1 1.1 1.2 1.4 1.7 1.8 1.6 1.7 2.0 Calcium/calmodulin-dependent protein
kinase I
503602 CAMK2N1 1.1 −1.7 −2.3 −2.6 −2.1 −2.9 −2.3 −3.0 Calcium/calmodulin-dependent protein
kinase II inhibitor 1
82225 SFRP1 −1.3 −1.2 −1.6 −2.2 −2.2 −2.2 −3.7 −4.4 Secreted frizzled-related protein 1
669375 DKK1 c 1.6 1.7 −1.6 −1.8 −4.1 −1.8 −2.8 −5.4 Dickkopf homolog 1 (Xenopus laevis)
323636 WNT5B −1.0 1.7 −1.1 −1.6 −1.8 −1.6 −1.6 −2.2 Wingless-type MMTV integration site family,
member 5B
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Table 1 (continued)
Category Clone ID Symbol 6 h 12 h 18 h 24 h 30 h 36 h 42 h 48 h Name
TGF-β pathway 32711 ACVR1 −1.1 −2.1 −4.3 −2.4 −3.2 −1.4 −1.6 −2.4 Activin A receptor, type I
824193 TGFBR1 c −1.4 −3.3 −4.1 −5.0 −3.2 −3.3 −4.3 −5.2 Transforming growth factor, beta receptor I
269815 INHBA c −1.6 −5.3 −12.5 −20.1 −21.1 −21.7 −23.6 −22.7 Inhibin, beta A (activin A, activin AB alpha
polypeptide)
742685 DAB2 c −1.1 −2.1 −2.8 −3.2 −2.5 −2.3 −3.4 −3.4 Disabled homolog 2, mitogen-responsive
phosphoprotein
324513 GREM1 −1.2 −1.5 −2.5 −4.6 −3.5 −3.4 −6.5 −8.2 Gremlin 1, cysteine knot superfamily, homolog
811821 SMURF1 −1.1 −1.5 −1.9 −2.1 −2.3 −2.1 −2.4 −2.6 SMAD-specific E3 ubiquitin protein ligase 1
379450 SMURF2 c 1.2 1.1 −2.0 −2.7 −2.3 −2.1 −2.5 −2.8 SMAD-specific E3 ubiquitin protein ligase 2
434768 FST 1.3 2.2 −1.5 −1.9 −2.7 −2.4 −3.2 −3.8 Follistatin
767202 LTBP2 −1.0 1.1 −1.1 −1.3 −1.6 −1.4 −1.7 −2.3 Latent transforming growth factor beta binding
protein 2
843398 BMP2 1.3 1.1 −1.3 −1.4 −1.7 −1.6 −2.0 −1.7 Bone morphogenetic protein 2
813825 LTBP3 1.1 −1.1 1.2 1.1 −1.1 −1.1 −1.8 −2.0 Latent transforming growth factor beta binding
protein 3
Other 366414 UHRF1 – 3.1 4.9 3.6 4.1 3.0 2.2 3.1 Ubiquitin-like, containing PHD and ring finger
domains, 1
1534399 BRD2 1.1 2.3 1.7 1.2 −1.3 −1.6 −1.9 −2.2 Bromodomain containing 2
1589973 BOLA3 1.2 2.1 2.0 2.1 1.9 1.4 – 1.5 BolA-like 3 (E. coli)
42313 PHB 1.0 1.7 2.0 2.2 2.1 2.4 2.0 1.6 Prohibitin
146882 UBE2C – 1.1 2.2 3.0 3.8 1.8 1.8 1.9 Ubiquitin-conjugating enzyme E2C
246304 BTG3 −1.1 −1.2 1.9 2.2 2.6 2.8 2.1 2.4 BTG family, member 3
67221 FLT1 −1.2 1.5 1.8 1.6 2.0 2.4 1.4 −1.4 Fms-related tyrosine kinase 1
731023 WDR5 1.1 −1.0 1.4 1.7 1.3 2.1 2.3 1.5 WD repeat domain 5
85384 MOBKL2C −1.1 1.2 1.7 1.9 1.8 2.1 2.0 2.0 MOB1, Mps One Binder kinase activator-like
2C (yeast)
1032444 mimitin 1.2 1.5 1.7 1.5 1.8 1.7 1.9 2.3 Myc-induced mitochondria protein
731299 RSU1 1.1 1.3 1.6 1.8 1.9 1.7 1.7 2.2 Ras suppressor protein 1
769028 MEOX1 1.1 1.2 −1.1 −1.1 −1.2 −1.0 −1.4 −2.1 Mesenchyme homeobox 1
a Data excluded due to low intensity or high variation.
b Fold change in gene expression between infected and uninfected cells as measured by cDNA microarray analysis.
c Confirmed with quantitative real-time PCR (QRT-PCR), see Table 5.
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infection. Based on the observed temporal changes of the
expression patterns, the adenovirus infectious cycle can be
divided into four periods. The first period was from 0 to 12 hpi,
before any of the adenoviral genes had been expressed. At 6 hpi,
seven differentially expressed genes were identified; (data not
shown), CENPN (data not shown) and PTGS2 by microarray,
and DKK1, TGFBR1, TRAP1 and ELL2 by QRT-PCR analysis.
All of them, except PTGS2 and HSPA1L, were up-regulated.
Our previous studies identified eighteen cellular genes, which all
were up-regulated between 1 and 2 hpi (Granberg et al., 2006).
The observation that all these genes were up-regulated may be an
artifact since up-regulation of gene expression is likely to be
easier to detect than down-regulation since the latter requires
degradation of the mRNA to be detectable. Together, the results
show that the response of the host cell to the incoming virus is
very rapid. Most of the genes in this category have functions
linked to inhibition of cell growth. Consequently, growth
suppression seems to be the first response to the incoming
virus. Regulation of cellular gene expression during this period
must be independent of adenoviral gene expression and is likely
to be triggered by the attachment of the virus to cell surface
receptors, the entry process of the virus, its intracellular transport
along the microtubules or the possible intracellular recognition
of viral nucleic acids by Toll-like receptors. The second period
covered the time from 12 to 24 hpi when E1A expression startedand increased rapidly. During this period, there was a linear
increase in differentially expressed cellular genes and by 24 hpi,
the expression of over 460 cellular genes was altered. About
43% of them were up-regulated. At this time, the virus infection
had proceeded far into the early phase and the expression
changes should favor adenoviral DNA replication. It is
noteworthy that about 50% of those genes that have known
functions were involved in control of cell cycle, cell prolifera-
tion, and antiviral response. The third period was from 24 to
36 hpi. At this time, the virus has taken over the control of the
cellular metabolic machinery to enhance production of progeny
virus. No dramatic changes in host gene expression occurred in
this interval. The fourth period was from 42 to 48 hpi when a
cytopathic effect appeared. The number of differentially
expressed genes increased significantly, the majority of which
were down-regulated. A conspicuous group consisted of genes
that are involved in intra- and extra-cellular structure. Appar-
ently, at this time point, the virus changes its strategy from
reproduction to efficient release and spread of the progeny
through destruction of the cell. It could be argued that this down-
regulation was non-specific and the consequence of an imminent
cell death. However, this seems unlikely as a number of other
genes were up-regulated in this period (see Fig. 2, group III).
Thus, it appears that the regulation of host cell gene expression is
specific, is well organized and takes place in steps. The switch
from the first to the second period is primarily mediated by E1A,
Table 2
Deregulation of cellular genes implicated in anti-viral defense
Category Clone ID Symbol 6 h 12 h 18 h 24 h 30 h 36 h 42 h 48 h Name
Cytokines and
receptors
153025 LIF c −1.6b −2.9 −4.2 −4.8 −4.9 −4.0 −4.4 −7.5 Leukemia inhibitory factor (cholinergic
differentiation factor)
146671 IL1R1 −1.0 −2.7 −2.9 −3.1 −2.6 −2.7 −3.2 −3.4 Interleukin 1 receptor, type I
310406 IL6 −1.8 −5.0 −8.1 −7.8 −5.0 −3.0 −5.6 −5.9 Interleukin 6 (interferon, beta 2)
1681719 IL11 −1.3 −1.3 −4.5 −4.0 −6.3 −6.5 −4.0 −5.3 Interleukin 11
768561 CCL2 1.1 −1.9 −4.2 −3.8 −3.0 −2.9 −1.8 −2.9 Chemokine (C–C motif) ligand 2
784337 CXCL12 −1.0 1.1 −1.9 −3.2 −2.2 −1.8 −2.0 −2.1 Chemokine (C–X–C motif) ligand 12
714453 IL4R −1.2 −1.3 −1.5 −1.6 −1.9 −1.8 −1.7 −2.1 Interleukin 4 receptor
812244 CMTM1 – a −1.0 1.7 2.2 3.0 2.3 2.4 3.8 CKLF-like MARVEL transmembrane domain
containing 1
NFκB 433491 NALP12 1.1 −2.4 −4.5 −3.0 −4.0 −4.6 −2.3 −3.5 NACHT, leucine-rich repeat and PYD containing 12
770670 TNFAIP3c −1.4 −2.0 −3.4 −2.9 −2.3 −2.1 −2.6 −3.6 Tumor necrosis factor, alpha-induced protein 3
789357 NFKB1c −1.2 −1.6 −1.7 −2.2 −2.1 −2.1 −2.4 −2.9 Nuclear factor of kappa light polypeptide gene
enhancer in B-cells 1 (p105)
340734 NFKBIAc 1.1 −1.4 −2.0 −2.0 −1.9 −2.4 −2.0 −2.3 Nuclear factor of kappa light polypeptide gene
enhancer in B-cells inhibitor, alpha
137971 NKIRAS2 c 1.1 1.0 −1.3 −1.5 −1.9 −1.9 −1.8 −2.3 NFκB inhibitor interacting Ras-like 2
382649 GPR177 −1.1 −1.1 1.1 −1.2 −1.3 −1.6 −2.1 −2.0 G protein-coupled receptor 177
813807 RNF25c 1.1 −1.2 −1.2 −1.3 −1.8 −1.5 −1.7 −2.4 Ring finger protein 25
52724 CC2D1A −1.0 1.3 2.0 2.4 1.9 1.9 2.0 1.6 Coiled-coil and C2 domain containing 1A
1946534 LTB 1.1 1.1 −1.0 1.1 2.1 1.4 2.1 2.0 Lymphotoxin beta (TNF superfamily, member 3)
809609 COMMD4 c 1.2 1.4 1.5 1.9 1.9 2.0 1.5 2.5 COMM domain containing 4
282710 PTPLAD1 −1.1 1.0 1.4 1.7 1.9 2.4 1.9 2.0 Protein tyrosine phosphatase-like A domain
containing 1
Apoptosis 365098 BNIP3L −1.2 −2.4 −3.7 −4.1 −2.6 −2.5 −3.0 −3.3 BCL2/adenovirus E1B 19 kDa interacting
protein 3-like
294496 HIPK2 1.1 −1.3 −2.2 −3.0 −3.3 −3.2 −3.5 −4.1 Homeodomain-interacting protein kinase 2
811101 SH3RF1 −1.0 −1.5 −3.1 −3.4 −3.8 −2.8 −3.1 −3.3 SH3 domain containing ring finger 1
665356 TNFRSF11B 1.4 −1.2 −2.0 −2.7 −2.4 −3.2 −2.3 −3.2 Tumor necrosis factor receptor superfamily,
member 11b
1597813 NALP1 1.2 1.6 −1.1 −1.4 −1.7 −1.9 −2.0 −2.4 NACHT, leucine rich repeat and PYD
(pyrin domain) containing 1
258547 PTRH2 −1.0 1.2 1.1 −1.1 1.1 −1.1 −2.1 −2.1 Peptidyl-tRNA hydrolase 2
898237 BAT3 −1.1 −1.3 −1.4 −1.6 −1.5 −1.6 −1.5 −2.3 HLA-B-associated transcript 3
120015 STK4 1.1 −1.0 −1.6 −1.6 −1.6 −1.6 −1.8 −2.2 Serine/threonine kinase 4
344282 FAF1 c −1.7 −1.2 1.1 1.7 1.6 2.5 1.8 1.8 Fas (TNFRSF6)-associated factor 1
731304 PDCD5 1.2 1.5 1.7 2.0 1.8 1.7 1.9 2.1 Programmed cell death 5
814584 CRR9 −1.1 −1.4 1.1 1.7 1.9 3.1 2.1 1.3 Cisplatin resistance-related protein CRR9p
70692 SERPINB2nc 1.1 3.8 6.2 5.8 5.0 3.5 2.2 2.5 Serpin peptidase inhibitor, clade B
(ovalbumin), member 2
897570 TRAP1c 1.0 1.7 2.3 2.5 2.5 2.5 2.1 1.9 TNF receptor-associated protein 1
34852 BIRC2 1.0 −1.3 −1.9 −2.2 −2.1 −2.0 −1.9 −2.5 Baculoviral IAP repeat containing 2
Jak/Stat 755599 IFITM1 1.1 −1.2 −1.8 −2.1 −1.9 −1.8 −1.6 −1.7 Interferon-induced transmembrane protein 1 (9–27)
84211 SOCS3 −1.0 1.5 −1.1 −1.4 −1.6 −1.7 −2.0 −2.4 Suppressor of cytokine signaling 3
772446 STAT3 1.0 −1.4 −1.7 −1.9 −1.8 −1.7 −2.0 −2.5 Signal transducer and activator of transcription 3
40178 ASB1 1.1 −1.2 −1.6 −1.8 −1.9 −1.9 −1.7 −2.0 Ankyrin repeat and SOCS box containing 1
Other 435434 CD14 −1.0 1.1 1.8 2.3 2.4 3.5 2.0 2.9 CD14 molecule
147050 PTGS2c −2.1 −4.9 −6.4 −5.7 −3.3 −3.6 −3.1 −3.2 Prostaglandin-endoperoxide synthase 2
271198 NR3C1 −1.2 −2.4 −2.2 −2.8 −2.6 −2.9 −2.9 −3.7 Nuclear receptor subfamily 3, group C, member 1
511303 PLA2R1 −1.2 −1.6 −6.1 −16.1 −18.1 −19.9 −17.4 −22.9 Phospholipase A2 receptor 1, 180 kDa
1928791 F3 1.1 −1.6 −2.2 −1.9 −2.3 −2.5 −1.5 −1.7 Coagulation factor III (thromboplastin, tissue factor)
1901363 KLRD1 −1.0 1.3 −1.1 −1.5 −1.6 −1.7 −2.2 −2.1 Killer cell lectin-like receptor subfamily D, member 1
436554 MPO 1.1 1.7 1.9 2.1 1.7 1.8 1.9 1.8 Myeloperoxidase
208718 ANXA1 1.1 1.2 1.0 −1.3 −1.3 −1.5 −1.7 −2.0 Annexin A1
785293 HRASLS3 – 1.2 1.5 1.6 1.8 1.9 2.0 2.0 HRAS–like suppressor 3
346860 SOD2 1.2 −1.8 −2.0 −2.1 −1.8 −2.0 −1.9 −2.1 Superoxide dismutase 2, mitochondrial
85634 C1S −1.0 −1.1 −1.5 −1.8 −1.3 −1.4 −1.6 −2.3 Complement component 1, s subcomponent
451256 C5 1.1 −1.2 −1.5 −1.6 −1.9 −1.6 −1.7 −2.1 Complement component 5
344134 IGLL1 1.3 2.0 1.1 −1.2 −1.7 −1.8 −2.1 −2.5 Immunoglobulin lambda-like polypeptide 1
878182 A2M 1.0 −1.1 −1.5 −1.8 −1.9 −1.8 −2.2 −2.1 Alpha-2-macroglobulin
486179 NFAT5 1.0 −1.0 −1.5 −1.9 −1.9 −1.7 −2.0 −1.9 Nuclear factor of activated T-cells 5,
tonicity-responsive
a, b and c as described in Table 1. nc Could not be confirmed with QRT-PCR, see Table 5.
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Table 3A
Differentially expressed cellular genes involved in DNA metabolism
Clone ID Symbol 6 h 12 h 18 h 24 h 30 h 36 h 42 h 48 h Name
450711 CHAF1A – a 2.9b 4.1 3.9 4.1 2.9 3.3 4.0 Chromatin assembly factor 1, subunit A (p150)
813586 GMNN – 1.1 3.3 3.9 3.5 2.3 – 4.6 Geminin, DNA replication inhibitor
512410 RNASEH2A −1.0 1.5 2.2 2.4 3.0 2.2 2.3 2.9 Ribonuclease H2, large subunit
745360 HAT1 −1.0 1.1 2.2 2.5 2.5 3.0 1.9 2.0 Histone acetyltransferase 1
433162 POLE – 1.8 2.1 2.5 2.0 1.7 1.6 1.8 Polymerase (DNA-directed), epsilon
203275 RFC4 1.1 1.5 2.3 2.5 1.9 2.0 1.6 2.1 Replication factor C (activator 1) 4, 37 kDa
256260 RFC3 – 1.7 2.4 2.4 1.7 2.3 – 1.4 Replication factor C (activator 1) 3, 38 kDa
771206 POLD2 −1.0 1.8 1.8 2.0 1.6 1.9 1.4 1.4 Polymerase (DNA-directed), delta 2, regulatory
subunit 50 kDa
825265 POLD3 – 1.7 2.2 2.3 – 2.1 1.3 1.5 Polymerase (DNA-directed), delta 3, accessory subunit
46248 PARP1 1.0 1.2 2.3 2.7 3.3 3.7 3.0 3.8 Poly(ADP-ribose) polymerase family, member 1
447208 EXO1 – – 2.9 2.9 2.5 – – 3.4 Exonuclease 1
878676 XRCC5 −1.1 1.2 1.6 2.1 2.4 2.5 1.6 1.4 X-ray repair complementing defective repair in
Chinese
hamster cells 5
41789 RAD18 – – 2.5 2.6 1.9 1.9 2.0 2.6 RAD18 homolog (S. cerevisiae)
451907 ZWINT – – 3.3 6.4 5.2 4.1 4.5 6.3 ZW10 interactor
1600239 Pfs2 – – 4.0 6.1 5.1 5.9 5.6 6.0 DNA replication complex GINS protein PSF2
241826 HMGN2 1.0 1.4 2.6 3.5 4.4 5.2 3.2 3.1 High-mobility group nucleosomal binding domain 2
379920 TK1 1.2 – 2.1 2.8 3.6 3.0 2.7 2.7 Thymidine kinase 1, soluble
123971 DHFRc 1.0 1.5 2.2 2.5 3.0 3.3 2.4 3.4 Dihydrofolate reductase
624627 RRM2 −1.1 1.3 2.1 2.8 2.8 3.2 2.4 1.8 Ribonucleotide reductase M2 polypeptide
741841 DDX12 1.0 1.5 2.3 2.1 1.7 1.6 1.4 1.8 DEAD/H (Asp-Glu-Ala-Asp/His) box polypeptide 12
358162 SAC3D1 – – 2.3 2.5 2.3 1.7 2.1 2.3 SAC3 domain containing 1
1461138 HIST1H4C 1.3 – 2.4 3.5 2.3 – 1.4 1.0 Histone 1, H4c
713127 SMC4L1 1.1 1.6 2.1 2.8 2.2 2.4 1.8 2.1 SMC4 structural maintenance of chromosomes
4-like 1 (yeast)
897997 SMC1L1 1.1 1.7 2.0 2.3 2.3 2.3 1.6 2.3 SMC1 structural maintenance of chromosomes
1-like 1 (yeast)
110744 hCAP-H2 1.1 1.4 1.8 2.0 2.0 1.8 2.0 2.0 Kleisin beta
825470 TOP2A −1.1 1.0 1.7 2.1 1.8 1.6 1.4 1.8 Topoisomerase (DNA) II alpha 170 kDa
1675553 HIST1H2BJ 1.1 1.0 1.4 2.0 3.0 3.2 3.1 3.3 Histone 1, H2bj
1500000 HIST1H2BD 1.1 1.1 1.5 1.9 2.8 3.1 2.9 3.2 Histone 1, H2bd
201125 HIST1H2BG 1.1 1.1 1.3 1.6 2.7 3.1 2.9 3.0 Histone 1, H2bg
430235 HIST2H2BE 1.1 1.0 1.2 1.6 2.5 2.7 2.2 2.7 Histone 2, H2be
290841 HIST1H2BK 1.1 1.1 1.2 1.6 2.1 2.4 2.2 2.3 Histone 1, H2bk
884531 CMPK −1.1 1.4 1.9 1.8 2.2 2.4 1.9 2.2 Cytidylate kinase
1917941 H2AFV 1.1 1.1 1.5 1.8 2.0 2.1 1.8 1.8 H2A histone family, member V
1571910 DEK −1.1 1.3 1.6 1.8 2.2 1.9 1.7 1.6 DEK oncogene (DNA binding)
756418 REPIN1 −1.1 1.5 1.5 1.7 1.5 2.1 1.7 1.3 Replication initiator 1
31873 HMGN4 −1.0 1.0 1.2 1.6 1.6 2.2 1.7 1.4 High mobility group nucleosomal binding domain 4
221808 NAP1L4 −1.3 −1.2 1.1 1.3 1.3 2.0 1.8 1.3 Nucleosome assembly protein 1-like 4
462318 RCC1 1.2 1.0 1.7 1.8 2.0 1.9 2.0 3.3 Regulator of chromosome condensation 1
259579 RAD51L3 1.0 −2.1 −4.2 −3.6 −3.9 −3.6 −4.1 −3.3 RAD51-like 3 (S. cerevisiae)
281892 NT5E 1.2 −1.5 −2.0 −2.3 −2.6 −2.8 −2.4 −2.7 5′-nucleotidase, ecto (CD73)
814109 POLS 1.0 −1.6 −1.3 −1.5 −1.8 −2.1 −1.9 −1.9 Polymerase (DNA-directed) sigma
283315 POLM 1.1 −1.2 −1.8 −1.9 −1.8 −1.4 −1.5 −2.1 Polymerase (DNA-directed), mu
a, b and c as described in Table 1.
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be caused by the expression of late adenovirus proteins as
discussed previously (Zhao et al., 2003).
Based on the known functions of adenoviral genes and the
observed profiles of cellular gene expression, it is possible to
speculate about the causes of the changes. Firstly, it is known
that adenoviruses interfere with the pRb–E2F pathway. This
regulation is achieved by direct interaction between E1A and
pRb, which allows for the release of transcription factor E2F and
activation of its target genes (Cobrinik, 1996). We show here
(Table 6) that a significant fraction of the up-regulated genes at
12 hpi (28%), 18 hpi (17%) and 24 hpi (17%) are E2F targets(Ishida et al., 2001; Muller et al., 2001; Polager et al., 2002;
Semizarov et al., 2004; Vernell et al., 2003). Nearly all of these
genes are involved in the cell cycle control, cell growth, and
DNA metabolism. A second set of genes is those implicated in
the NFκB pathway. NFκB plays a very important role in host
cell immune response and regulates the expression of several
hundred target genes (Ghosh et al., 1998). We show here that
NFκB was down-regulated at 24 hpi and throughout the
infection. The suppression of the NFκB pathway was further
enhanced by down-regulation of the two positive regulators,
RNF25 andGPR177, as well as by up-regulation of the negative
regulator COMMD4. The down-regulation of NFKBIA may
Table 3B
Differentially expressed cellular genes involved in RNA synthesis
Clone ID Symbol 6 h 12 h 18 h 24 h 30 h 36 h 42 h 48 h Name
1635364 LSM2 1.1b 2.1 2.7 2.9 2.2 1.9 1.8 1.6 LSM2 homolog, U6 small nuclear RNA-associated
247076 SNRPA −1.2 1.2 2.3 2.6 2.9 3.5 2.8 2.4 Small nuclear ribonucleoprotein polypeptide A
704414 SNRPB 1.2 1.6 2.3 4.1 8.2 7.3 6.7 6.4 Small nuclear ribonucleoprotein polypeptides B and B1
80399 SFRS1 1.3 1.8 2.4 2.2 2.1 1.6 1.4 1.4 Splicing factor 2, alternate splicing factor
257504 FUSIP1 −1.0 1.2 2.0 1.5 1.4 1.4 1.2 1.1 FUS interacting protein 1
1559703 EXOSC5 – a 1.8 2.7 3.0 3.7 3.0 2.8 3.5 Exosome component 5
246116 RNPC3 1.1 1.2 1.8 2.3 4.1 3.5 3.2 4.3 RNA-binding region (RNP1, RRM) containing 3
248965 RPP30 −1.1 1.3 1.8 2.5 2.5 2.5 2.4 2.2 Ribonuclease P/MRP 30 kDa subunit
796176 LSM3 1.1 1.3 1.6 2.1 2.5 2.6 2.2 2.4 LSM3 homolog, U6 small nuclear RNA-associated
852913 SNRPF 1.2 1.6 1.8 2.0 2.3 2.1 1.4 2.2 Small nuclear ribonucleoprotein polypeptide F
724387 SNRPC 1.2 1.5 1.7 1.9 2.0 2.2 2.1 2.1 Small nuclear ribonucleoprotein polypeptide C
825012 LSMD1 1.1 1.3 1.5 2.0 2.0 2.1 2.2 2.3 LSM domain containing 1
767277 PPIH – 1.3 1.5 2.0 1.7 2.0 2.1 2.6 Peptidylprolyl isomerase H (cyclophilin H)
611028 RBMX −1.2 1.3 1.8 2.0 2.1 2.6 1.7 1.3 RNA binding motif protein, X-linked
855755 FBL 1.0 1.4 1.8 2.3 2.3 2.5 1.9 1.8 Fibrillarin
811097 NOLA2 1.1 1.5 1.7 2.1 2.3 2.5 2.1 1.9 Nucleolar protein family A, member 2
810613 DDX49 1.2 1.7 1.9 2.1 2.1 2.0 2.1 2.1 DEAD (Asp-Glu-Ala-Asp) box polypeptide 49
250519 DDX46 – −1.1 1.2 1.5 1.4 2.3 1.5 2.2 DEAD (Asp-Glu-Ala-Asp) box polypeptide 46
838373 DHX9 −1.2 −1.1 1.6 1.9 1.8 2.8 1.7 1.3 DEAH (Asp-Glu-Ala-His) box polypeptide 9
149416 DDX18 −1.2 1.0 1.1 −1.3 −1.2 −2.0 – −1.6 DEAD (Asp-Glu-Ala-Asp) box polypeptide 18
324672 ELL2c −1.0 −1.3 −2.2 −3.2 −1.7 −2.5 −2.6 −2.8 Elongation factor, RNA polymerase II, 2
452963 CUGBP1 1.1 −1.2 −1.3 −1.5 −1.8 −2.1 −1.9 −2.3 CUG triplet repeat, RNA binding protein 1
796137 TCEA1 −1.1 1.1 −1.3 −1.7 −1.8 −2.0 −1.7 −1.9 Transcription elongation factor A (SII), 1
767993 PTRF 1.0 1.2 −1.3 −1.7 −1.7 −1.7 −2.4 −3.4 Polymerase I and transcript release factor
1606780 KHDRBS1 1.1 −1.4 −1.8 −1.8 −1.9 −1.9 −2.3 −2.7 KH domain containing, RNA binding, signal
transduction-associated 1
590390 ZCRB1 1.0 −1.4 −1.7 −1.9 −1.9 −1.7 −2.5 −2.0 Zinc finger CCHC-type and RNA binding motif 1
809535 SFRS2 1.2 1.4 1.5 1.4 1.0 −1.3 −1.6 −2.0 Splicing factor, arginine/serine-rich 2
460260 RBM25 1.0 −1.1 1.0 −1.0 −1.4 −1.9 −1.9 −2.1 RNA binding motif protein 25
788415 MKI67IP 1.1 1.1 1.2 −1.0 −1.1 −1.4 −1.9 −2.3 MKI67 (FHA domain) interacting nucleolar
phosphoprotein
a, b and c as described in Table 1.
366 H. Zhao et al. / Virology 363 (2007) 357–375seem enigmatic as it is an inhibitor of NFκB, however it may
simply reflect the fact that its expression is regulated by NFκB.
In our study, we could show that 32 out of 33 known NFκB
targets were down-regulated (data not shown).
As described above, conflicting results relating to the
regulation of a few genes were occasionally observed in this
study. This might reflect the ongoing battle between the virus
and its host cell. In particular, the regulation of cellular genes
implicated in the cellular apoptotic pathway is not simple and
straightforward. As shown in Table 7, among 14 transiently up-
regulated cellular genes (with known functions) at 12 hpi, five
(GADD45B, ID3, FST, BRD2 and SRM) were p53-targeted
genes (Kannan et al., 2001; Wang et al., 2001; Wei et al.,
2006), suggesting that p53 was activated. The activation of p53
at the early stage is likely to reflect an immediate response of
the host cell, since at this time the E1A genes have just began
to be expressed. Furthermore, GADD45B and ID3 are well-
known stress response genes. The expression of these genes
declined gradually to the same level as in mock-infected cells
or became down-regulated during the late phase of the
infection. It is likely that the E1B genes, together with other
viral early genes, block p53 transcriptional activity. In addition,
we have detected altered expression of several genes involved
in the FAS, NFκB and TNF signaling pathways, which lead to
apoptosis (see Table 2), indicating that the suppression ofapoptosis by adenovirus is very comprehensive. Still, expres-
sion of numerous pro-apoptotic genes, such as PDCD5, FAF1
and CRR9, was up-regulated, whereas some anti-apoptotic
genes, including BIRC2 and SERPINB2 (shown by QRT-
PCR), were down-regulated. This suggests that the struggle
against cellular apoptosis is very complex.
Regulation of the expression of cellular genes involved in
the TGF-β signaling pathway represents another example of
the complexity in control of cellular gene expression. We
showed here that all detected genes implicated in the TGF-β
pathway, both negative and positive regulators, were down-
regulated in the primary cell. Down-regulation of TGF-β
superfamily members, BMP2 and INHBA, and their receptors,
TGFBR1 and ACVR1, suggested inhibition of the TGF-β
signaling pathway. These results are consistent with earlier
reports in which the expression of the TGF-β receptor was
found to be down-regulated in E1A-transformed keratinocytes
(Kim et al., 1997; Missero et al., 1991). E1A has also been
shown to block TGF-β-mediated induction of p21, p15 and
JunB (Coussens et al., 1994; Datto et al., 1997; de Groot et
al., 1995). E1A blocks growth inhibition by TGF-β through
to its ability to bind hypophosphorylated pRb (Missero et al.,
1991; Pietenpol et al., 1990) and SMAD proteins (Nishihara
et al., 1999). The inhibitory effect on TGF-β by adenovirus
was also observed in our previously study (Zhao et al., 2003).
Table 4A
Deregulation of cellular genes involved in intracellular cytoskeleton
Category Clone ID Symbol 6 h 12 h 18 h 24 h 30 h 36 h 42 h 48 h Name
Actin filaments 460646 MYO10 1.0b −1.0 −2.3 −2.8 −3.7 −3.9 −3.6 −4.0 Myosin X
562778 PDLIM5 −1.2 −1.5 −2.9 −2.0 −2.0 −1.5 −1.5 −2.3 PDZ and LIM domain 5
753418 VASP 1.1 −1.2 −1.8 −2.1 −2.3 −2.0 −2.2 −3.4 Vasodilator-stimulated phosphoprotein
770080 PXN 1.0 1.1 −1.8 −2.6 −2.8 −3.0 −2.6 −3.2 Paxillin
510088 KLHL5 −1.1 −1.5 −1.9 −2.0 −1.8 −1.8 −1.8 −1.8 Kelch-like 5 (Drosophila)
811096 ITGB4 −1.1 −1.7 −1.9 −2.2 −1.8 −1.8 −1.8 −2.0 Integrin, beta 4
854079 ACTN1 −1.0 1.0 −1.4 −2.0 −2.3 −2.3 −3.0 −4.1 Actinin, alpha 1
131362 MSN 1.1 1.2 1.0 −1.3 −1.6 −2.1 −2.2 −2.1 Moesin
755444 TMSB4X 1.1 1.0 −1.5 −1.8 −1.8 −2.0 −2.7 −2.5 Thymosin, beta 4, X-linked
1631663 LASP1 1.1 1.2 −1.2 −1.8 −1.9 −1.9 −2.6 −2.9 LIM and SH3 protein 1
683059 CDC42EP3 1.2 1.5 −1.6 −1.7 −1.7 −1.7 −2.1 −2.4 CDC42 effector protein
(Rho GTPase binding) 3
897868 PPP1R9B 1.0 −1.1 −1.3 −1.4 −1.4 −1.4 −2.0 −1.9 Protein phosphatase 1, regulatory subunit
9B, spinophilin
811740 ITGA2 −1.0 −1.3 −1.4 −1.8 −2.0 −1.9 −2.1 −2.6 Integrin, alpha 2
753453 PHACTR2 −1.1 −1.3 −1.5 −1.7 −1.3 −1.4 −1.8 −2.3 Phosphatase and actin regulator 2
1631634 ARPC5L 1.0 −1.5 −1.4 −1.3 −1.3 −1.6 −1.9 −2.1 Actin-related protein 2/3 complex,
subunit 5-like
841498 MRLC2 1.1 1.1 −1.2 −1.7 −1.5 −1.5 −1.9 −2.0 Myosin regulatory light chain MRLC2
1627806 ENAH −1.2 −1.6 −1.9 −1.7 −1.6 −1.7 −1.5 −2.4 Enabled homolog (Drosophila)
165828 FHOD1 −1.2 1.1 −1.0 −1.2 −1.8 −1.3 −1.8 −2.1 Formin homology 2 domain containing 1
325370 COTL1 −1.0 −1.1 −1.3 −1.5 −2.0 −1.5 −1.9 −2.1 Coactosin-like 1
1603346 EPB41 −1.1 −1.1 1.1 1.3 1.8 2.2 2.0 2.1 Erythrocyte membrane protein band 4.1
1643138 RHOF −1.0 −1.1 1.1 1.3 1.6 1.4 2.1 2.2 Ras homolog gene family, member F
(in filopodia)
37895 PDE4DIP −1.1 −1.1 1.1 1.4 1.8 1.8 2.0 2.5 Phosphodiesterase 4D interacting protein
Microtubules 291216 CETN2 −1.0 −1.7 −2.6 −2.3 −2.5 −2.3 −2.2 −2.3 Centrin, EF-hand protein, 2
796650 MAP1LC3B 1.0 −1.6 −2.2 −2.1 −1.7 −1.4 −2.1 −2.0 Microtubule-associated protein 1 light
chain 3 beta
50282 MAP1B −1.0 −1.2 −1.8 −2.5 −2.3 −2.4 −2.8 −3.4 Microtubule-associated protein 1B
753038 KIFC3 1.2 −1.1 −1.5 −1.8 −2.1 −1.7 −1.6 −2.0 Kinesin family member C3
786265 MICAL2 1.1 1.1 −1.2 −1.7 −2.5 −1.8 −2.2 −2.5 Microtubule-associated monooxygenase,
calponin and LIM domain containing 2
795856 BPY2IP1 1.1 −1.6 −1.7 −1.5 −1.8 −2.0 –a −2.2 BPY2 interacting protein 1
122428 HOOK2 −1.1 1.3 −1.2 −1.6 −2.0 −2.3 −2.4 −3.2 Hook homolog 2 (Drosophila)
878178 PAFAH1B1 −1.0 1.2 −1.2 −1.4 −1.7 −1.6 −2.2 −2.2 Platelet-activating factor acetylhydrolase,
isoform Ib, alpha subunit 45 kDa
173145 CLIPR-59 −1.1 −1.4 −1.6 −1.7 −1.4 −1.5 −2.0 −2.7 CLIP-170-related protein
853938 DYNLL1 1.6 2.1 1.2 −1.0 −1.4 −1.6 −2.0 −2.1 Dynein, light chain, LC8-type 1
1636876 TUBB2C 1.1 1.4 1.2 1.1 1.1 −1.1 −1.6 −2.6 Tubulin, beta 2C
254010 TUBE1 −1.2 1.4 1.7 1.5 1.9 2.4 1.3 −1.4 Tubulin, epsilon 1
251612 TBCA 1.0 1.0 1.2 1.4 1.8 1.6 2.4 2.6 Tubulin-specific chaperone a
450455 TTL 1.0 −1.2 1.1 1.4 1.4 2.1 1.9 2.7 Tubulin tyrosine ligase
Intermediate
filaments
781362 PLEC1 1.1 1.2 −1.1 −1.3 −2.2 −2.4 −2.6 −3.3 Plectin 1, intermediate filament binding
protein 500 kDa
840511 VIM 1.0 1.2 1.0 −1.0 −1.1 −1.2 −1.9 −2.5 Vimentin
815501 LMNB2 1.1 1.4 1.6 1.8 2.0 2.0 – 1.9 Lamin B2
a and b as described in Table 1.
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was down-regulated, whereas SMURF1 was up-regulated. In
contrast to previous reports, we find in this study that the
expression of SMURF1 and SMURF2, which induce the
degradation of SMADs, were both down-regulated, suggest-
ing that the TGF-β pathway might maintain some activity at
the protein level. Our Western blot analysis showed that the
expression of SMADs at the protein level remained stable
(SMAD2 and SMAD1/3) or increased (SMAD4) from 18 hpi
until very late in the infection. Apparently, regulation of TGF-
β during an adenovirus infection occurs at different levels and
is mediated by several different mechanisms. It is plausiblethat the increase in the level of SMAD proteins might
represent an attempt by the primary cell to counteract the
inhibitory effect on the TGF-β pathway by adenovirus. This
might be one of the reasons why the adenovirus replication
cycle is slower in the primary cells as compared to that in
HeLa cells. However, the TGF-β pathway was evidently
blocked, at least to some extent, as indicated by the down-
regulation of novel TGF-β target genes, such as COL1A1,
COL6A1, COL6A3 and CD44 (shown in Table 4C) during
the late phase of the infection (Verrecchia et al., 2001).
Several genes involved in the Wnt signaling pathway were
differentially expressed. Like the TGF-β pathway, the Wnt
Table 4B
Deregulation of cellular genes involved in membrane–vesicles transport
Clone ID Symbol 6 h 12 h 18 h 24 h 30 h 36 h 42 h 48 h Name
2012523 STX3A 1.2b 2.1 2.8 3.3 3.6 4.3 3.6 4.0 Syntaxin 3A
1639531 RAB27A −1.3 – a 1.8 2.4 2.3 2.5 2.5 2.6 RAB27A, member RAS oncogene family
1584310 SYT13 – 1.2 1.0 1.7 2.2 2.5 2.6 2.6 Synaptotagmin XIII
399456 STX4A −1.0 1.0 1.1 1.1 1.6 1.4 2.0 2.3 Syntaxin 4A (placental)
32160 SEC23B −1.0 1.8 1.9 2.1 1.8 1.6 1.6 1.5 Sec23 homolog B (S. cerevisiae)
292482 STON2 −1.0 1.1 1.3 1.3 2.3 1.9 1.8 2.3 Stonin 2
343167 SAR1B 1.1 −1.0 1.3 1.6 1.4 2.1 1.2 1.2 SAR1 gene homolog B (S. cerevisiae)
1604320 EPN2 −1.0 −1.1 1.1 1.4 1.7 1.7 2.0 2.2 Epsin 2
42008 RAB6IP1 −1.3 −2.2 −2.0 −2.0 −2.3 −1.4 −2.2 −3.1 RAB6 interacting protein 1
453230 RAB11FIP1 −1.1 −1.6 −2.3 −2.3 −2.4 −2.0 −1.8 −2.5 RAB11 family interacting protein 1 (class I)
878462 RABGEF1 −1.0 −1.4 −2.1 −2.3 −2.3 −2.0 −2.5 −2.6 RAB guanine nucleotide exchange
factor (GEF) 1
897626 RAB7 1.0 −1.0 −1.1 −1.3 −1.2 −1.1 −1.8 −2.1 RAB7, member RAS oncogene family
812155 RABGGTB 1.1 −1.1 −1.0 −1.2 −1.5 −1.7 −2.1 −2.0 Rab geranylgeranyltransferase, beta subunit
795529 STX6 1.1 −1.9 −2.9 −3.1 −2.4 −2.1 −2.1 −2.0 Syntaxin 6
811937 SNX9 1.0 −1.6 −2.1 −2.6 −2.2 −2.4 −2.4 −2.9 Sorting nexin 9
726695 SNX30 −1.0 −1.3 −1.8 −2.2 −2.5 −2.0 −2.3 −2.1 Sorting nexin family member 30
825356 SNAG1 1.0 −1.8 −1.9 −2.1 −1.9 −1.9 −1.9 −2.4 Sorting nexin-associated golgi protein 1
897153 TRAPPC4 −1.0 1.1 −1.0 −1.4 −1.8 −2.0 −2.1 −2.6 Trafficking protein particle complex 4
884540 SNX12 1.0 1.1 −1.2 −1.2 −1.4 −1.4 −2.2 −2.2 Sorting nexin 12
49389 STX1A 1.0 −1.1 −1.5 −1.6 −2.0 −1.5 −1.2 −1.5 Syntaxin 1A (brain)
785840 SEC24D 1.1 1.1 1.1 −1.2 −1.6 −1.5 −1.8 −2.0 SEC24-related gene family, member D
(S. cerevisiae)
843265 SEC31L1 1.1 1.1 −1.2 −1.4 −1.6 −1.7 −1.8 −2.5 SEC31-like 1 (S. cerevisiae)
897971 COPB 1.0 1.2 −1.1 −1.5 −1.6 −1.6 −2.1 −2.5 Coatomer protein complex, subunit beta
1635705 GOLGA2 1.0 1.2 −1.1 −1.3 −1.9 −2.2 −1.7 −2.2 Golgi autoantigen, golgin subfamily a, 2
1555502 NSFL1C −1.1 1.0 −1.3 −1.4 −1.2 −1.9 1.1 −2.0 NSFL1 (p97) cofactor (p47)
1631699 VCP 1.2 1.2 −1.1 −1.2 −1.4 −1.7 −2.2 −2.6 Valosin-containing protein
1635695 GGA2 1.1 1.5 −1.1 −1.5 −1.8 −1.4 −1.6 −2.0 Golgi-associated, gamma adaptin
ear-containing, ARF-binding protein 2
323474 ARF1 1.0 1.3 −1.0 −1.1 −1.2 −1.0 −1.7 −2.6 ADP-ribosylation factor 1
774071 PICALM 1.1 −1.1 −1.7 −2.2 −1.8 −1.8 −2.6 −2.3 Phosphatidylinositol binding clathrin
assembly protein
26198 EHD1 −1.2 −1.4 −2.6 −3.2 −3.1 −2.8 −3.6 −5.4 EH-domain containing 1
a and b as described in Table 1.
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adenovirus infection. Wnts are powerful regulators of cell
proliferation and differentiation. By 6 hpi, the expression of
DDK1 (identified by QRT-PCR as shown in Table 5) was
induced. DDK1 encodes a secretory protein of the dickkopf
family of inhibitors ofWnt-signaling. An inhibitory effect on the
Wnt pathway is likely to be another reflection of the cellular
antiviral response. However, the RNA level of DDK1 decreased
soon after E1A expression, and became down-regulated after
24 hpi, indicating that the suppression of the Wnt pathway was
blocked by adenovirus. Adenovirus seems to have additional
stimulatory effects on Wnt signaling by down-regulating
another secreted inhibitor of Wnt signaling, SFRP1, as well as
by up-regulating aWnt receptor, FZD7, and a coreceptor, LRP6.
Thus, it seems likely that Wnt signaling was activated after viral
gene expression had begun. However, certain negative effectors
on the Wnt pathway, such as APC, were up-regulated (Table 1).
APC encodes the adenomatous polyposis coli tumor-suppressor
protein, which targets β-catenin for degradation and thereby
blocks Wnt signaling (Nelson and Nusse, 2004). Activation of
Wnt signaling by different human tumor viruses has been
demonstrated previously, such as human polyoma virus JC,
Epstein–Barr virus, and Kaposi's sarcoma–assicated herpes-virus (Enam et al., 2002; Fujimuro et al., 2003; Morrison et al.,
2003). Different strategies for activation of the Wnt pathway
were used by these viruses. Here, we present the first evidence
for activation of Wnt signaling during adenovirus infection but
the molecular mechanism behind the deregulation of Wnt
signaling by adenovirus needs further study.
We have previously studied the host transcription profiles in
adenovirus-infected HeLa cells (Granberg et al., 2005; Zhao et
al., 2003). One hundred and seventy-three cellular genes were
identified as differentially expressed. Here, expression of nearly
1000 genes was found to be regulated during the course of an
adenovirus infection in IMR-90 cells. The dramatic increase in
gene number was due to the improved experimental set-up,
which included utilization of synchronized primary cells, and
the analysis of more time points after infection. Besides, a larger
array and a better labeling method was also used. We found that
32% of the genes previously identified as differentially
expressed in HeLa cells were not expressed at a detectable
level in adenovirus-infected IMR-90 cells. The remaining 106
genes were expressed in IMR-90 cells, but 49 of them were
unchanged during the infection. Fifty-seven genes, identified as
differentially expressed in both adenovirus-infected HeLa and
IMR-90 cells, displayed similar fold changes whereas three
Table 4C
Deregulation of cellular genes implicated in cell junction and extracellular matrix
Clone ID Symbol 6 h 12 h 18 h 24 h 30 h 36 h 42 h 48 h Name
85979 PLG 1.0b 2.7 5.0 4.4 3.4 3.2 2.3 2.3 Plasminogen
837870 PRELP 1.2 2.6 5.8 4.8 3.7 3.9 2.4 1.9 Proline/arginine-rich end leucine-rich repeat protein
214441 IGHG1 −1.0 1.5 2.0 2.0 2.3 2.1 1.6 1.7 Immunoglobulin heavy constant gamma 1 (G1m marker)
153520 CDH24 – a 1.8 2.5 2.3 2.9 1.9 2.3 3.0 Cadherin-like 24
897910 POSTN 1.0 1.8 2.4 2.1 1.5 2.5 2.7 1.3 Periostin, osteoblast-specific factor
856585 MMP19 – 1.1 1.7 2.1 2.1 2.5 1.6 1.9 Matrix metallopeptidase 19
1574438 MMP11 1.2 1.1 −1.1 1.2 2.1 1.4 2.3 1.8 Matrix metallopeptidase 11 (stromelysin 3)
726645 CLEC3A −1.1 −1.3 1.5 1.7 2.3 2.7 1.5 2.1 C-type lectin domain family 3, member A
360254 CYR61c −1.0 −2.4 −5.3 −5.6 −5.8 −6.6 −5.6 −4.4 Cysteine-rich, angiogenic inducer, 61
205185 THBD −1.3 −3.6 −2.7 −2.9 −2.2 −2.1 −1.7 −1.9 Thrombomodulin
666371 THBS1 −1.6 −3.3 −4.5 −5.2 −5.2 −3.8 −4.6 −8.3 Thrombospondin 1
813841 PLAT 1.0 −1.6 −4.1 −5.4 −6.3 −6.5 −8.1 −10.6 Plasminogen activator, tissue
448110 TIMP3 −1.2 −1.6 −3.3 −4.9 −5.8 −5.3 −5.5 −6.3 TIMP metallopeptidase inhibitor 3
810017 PLAUR −1.2 −1.5 −2.0 −2.0 −1.9 −2.7 −2.1 −2.2 Plasminogen activator, urokinase receptor
773242 VEZT 1.1 −1.3 −2.1 −2.5 −2.5 −2.5 −1.9 −2.5 Vezatin, adherens junctions transmembrane protein
770579 CLDN3 −1.2 −1.4 −2.5 −2.8 −3.8 −2.1 – −2.2 Claudin 3
770388 CLDN4 −1.2 −1.8 −5.6 −6.0 −4.2 −3.1 −3.4 −4.9 Claudin 4
809901 COL15A1 −1.1 −1.5 −2.0 −2.6 −2.7 −2.5 −3.0 −3.4 Collagen, type XV, alpha 1
50483 FBLN5 1.0 −1.2 −1.6 −2.1 −2.3 −2.3 −2.8 −3.8 Fibulin 5
813823 LUM 1.1 −1.1 −1.5 −2.0 −1.6 −1.5 −2.3 −3.0 Lumican
504763 SDC4 −1.1 −1.1 −1.8 −1.7 −2.1 −2.4 – −2.0 Syndecan 4 (amphiglycan, ryudocan)
502518 LAMB2 1.0 −1.2 −1.3 −1.5 −2.1 −2.0 −2.3 −2.8 Laminin, beta 2 (laminin S)
488258 COL16A1 1.0 1.1 −1.5 −1.3 −2.3 −2.1 −1.8 −1.9 Collagen, type XVI, alpha 1
1034494 ADAM19 1.1 1.0 −1.5 −1.5 −2.3 −1.9 −1.4 −1.6 ADAM metallopeptidase domain 19 (meltrin beta)
489755 ADAM12 −1.1 −1.1 −1.4 −1.6 −2.5 −1.8 −1.4 −1.7 ADAM metallopeptidase domain 12 (meltrin alpha)
739155 CDH6 1.0 1.3 −1.3 −2.0 −1.9 −2.3 −2.3 −2.3 Cadherin 6, type 2, K-cadherin (fetal kidney)
138991 COL6A3 1.0 −1.3 −1.3 −1.7 −2.0 −1.8 −2.5 −2.2 Collagen, type VI, alpha 3
153646 COL1A1 1.0 2.0 1.6 1.1 −1.4 −1.8 −2.8 −3.8 Collagen, type I, alpha 1
786609 COL12A1 −1.0 1.0 −1.2 −1.6 −1.5 −1.7 −2.1 −1.8 Collagen, type XII, alpha 1
714106 PLAU 1.2 1.9 −1.0 −1.7 −1.9 −1.9 −2.5 −2.7 Plasminogen activator, urokinase
1534435 TIMP2 1.0 −1.1 −1.3 −1.5 −1.5 −1.6 −2.0 −1.9 TIMP metallopeptidase inhibitor 2
262060 LOX 1.0 1.5 1.2 −1.1 −1.2 −1.2 −2.1 −1.8 Lysyl oxidase
813735 DCHS1 1.0 −1.4 −1.7 −1.9 −2.0 −1.1 −2.1 −2.2 Dachsous 1 (Drosophila)
1492230 EFEMP1 1.1 −1.3 −1.6 −2.0 −1.9 −1.9 −2.1 −2.2 EGF-containing fibulin-like extracellular matrix protein 1
431231 EFEMP2 −1.1 1.0 −1.2 −1.2 −1.5 −1.2 −1.5 −2.1 EGF-containing fibulin-like extracellular matrix protein 2
121722 FBN2 −1.2 −1.1 −1.3 −1.5 −1.2 −1.1 −1.7 −2.4 Fibrillin 2 (congenital contractural arachnodactyly)
502367 FBLN1 −1.1 −1.3 −1.6 −1.7 −1.6 −1.4 −1.6 −2.2 Fibulin 1
263716 COL6A1 1.0 1.1 −1.1 −1.3 −1.3 −1.2 −1.5 −2.0 Collagen, type VI, alpha 1
843222 COL5A1 −1.1 1.1 −1.1 −1.3 −1.7 −1.5 −1.5 −2.2 Collagen, type V, alpha 1
1474174 MMP2 −1.0 −1.1 −1.3 −1.5 −1.8 −1.6 −1.9 −2.1 Matrix metallopeptidase 2
23185 TNC −1.2 −1.1 −1.5 −1.9 −2.1 −1.9 −2.4 −4.0 Tenascin C (hexabrachion)
742125 LOXL1 −1.0 1.2 −1.1 −1.4 −1.8 −2.2 −2.4 −3.3 Lysyl oxidase-like 1
139009 FN1 1.0 −1.2 −1.5 −1.9 −1.6 −1.6 −2.6 −3.1 Fibronectin 1
126320 JUP −1.3 −1.4 −1.3 −1.8 −1.5 −1.6 −2.0 −2.7 Junction plakoglobin
713145 CD44 −1.1 −1.2 −1.4 −1.4 −1.6 −1.2 −1.8 −3.2 CD44 molecule (Indian blood group)
a, b and c as described in Table 1.
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HSPA1L and a gene without any known function (clone ID
285908). Whereas SMURF1 and HSPA1L were up-regulated in
HeLa cells and down-regulated in IMR-90 cells during
adenovirus infection, the opposite was observed for the gene
represented by clone 285908. The biological significance of the
differences in the regulation of SMURF1 during an adenovirus
infection in the two different cell lines was discussed earlier.
The reason for the differences in regulation of HSPA1L, a heat
shock protein-like, remains elusive.
Our microarray experiments represent just a starting point
towards the understanding of the interaction between adeno-
virus and its host cell. No single approach can fully unravel the
complexity of the regulatory events that govern the infectiouscycle. Additional studies encompassing bioinformatics, geno-
mics, and proteomics are clearly called for.
Material and methods
Cell culture, synchronization and cell phase analysis
Human primary lung fibroblast cells (IMR-90), purchased
from the American Type Culture Collection, were cultured in
Eagle's minimum essential medium (MEM) with Earle's salt
and GlutaMAX supplemented with 10% fetal bovine serum,
100 U/ml penicillin, 100 μg/ml streptomycin, 0.1 mM non-
essential amino acids, 1.5 g/l sodium bicarbonate and 1.0 mM
sodium pyruvate. The IMR-90 cells were synchronized by
Table 5
Confirmation of microarray results by QRT-PCR
Symbol Assay 6 h 12 h 18 h 24 h 30 h 36 h 42 h 48 h
CCNE1 Array – a – 2.5b 2.3 – – – –
RT-PCR −1.4d 3.4 6.7 1.9 4.4 3.3 3.1 2.6
DKK1 Array 1.6 1.7 −1.6 −1.8 −4.1 −1.8 −2.8 −5.4
RT-PCR 2.4 1.9 −1.7 −9.5 −13.4 −21.0 −33.4 −40.1
ELK3 Array 1.2 −1.2 −1.5 −1.9 −2.2 −2.4 −2.1 −2.1
RT-PCR −1.3 −1.1 −2.1 −15.1 −5.8 −6.4 −8.5 −11.9
INHBA Array −1.6 −5.3 −12.5 −20.1 −21.1 −21.7 −23.6 −22.7
RT-PCR −1.1 −5.9 −16.0 −59.0 −75.7 −93.9 −115.3 −102.9
JUN Array 1.3 1.1 −1.6 −2.1 −1.8 −2.0 −1.6 −2.0
RT-PCR 1.1 1.2 −1.4 −1.7 −2.8 −3.0 −5.4 −7.2
MYC Array 1.0 −1.6 −2.4 −3.1 −3.0 −2.8 −2.8 −3.1
RT-PCR −1.0 1.3 −1.7 −2.2 −3.3 −3.6 −4.7 −3.0
SMURF2 Array 1.2 1.1 −2.0 −2.7 −2.3 −2.1 −2.5 −2.8
RT-PCR 1.5 2.0 −1.3 −17.9 −3.5 −4.0 −4.4 −6.8
VEGF Array −1.7 −2.4 −2.7 −3.9 −3.6 −3.1 −4.1 −6.0
RT-PCR 1.1 1.0 −1.2 −8.7 −3.3 −1.7 −3.2 −5.0
DAB2 Array −1.1 −2.1 −2.8 −3.2 −2.5 −2.3 −3.4 −3.4
RT-PCR 1.1 −1.1 −1.3 −1.8 −1.3 −1.6 −1.9 −3.4
TGFBR1 Array −1.4 −3.3 −4.1 −5.0 −3.2 −3.3 −4.3 −5.2
RT-PCR 2.6 −1.2 −1.6 −5.1 −1.5 −1.6 −1.7 −3.0
ETS1 Array −1.6 −3.4 −5.2 −5.1 −3.0 −4.0 −3.2 −3.5
RT-PCR 1.3 −3.7 −5.4 −18.5 −7.0 −7.4 −10.5 −15.2
COMMD4 Array 1.2 1.4 1.5 1.9 1.9 2.0 1.5 2.5
RT-PCR 1.6 1.3 1.2 1.7 2.3 2.2 1.7 1.1
LIF Array −1.6 −2.9 −4.2 −4.8 −4.9 −4.0 −4.4 −7.5
RT-PCR 1.2 −2.1 −4.0 −15.1 −17.8 −16.8 −22.7 −29.6
NFKB1 Array −1.2 −1.6 −1.7 −2.2 −2.1 −2.1 −2.4 −2.9
RT-PCR −1.4 −3.2 −4.4 −6.7 −9.1 −13.7 −16.8 −23.7
NFKBIA Array 1.1 −1.4 −2.0 −2.0 −1.9 −2.4 −2.0 −2.3
RT-PCR 1.1 −2.3 −4.4 −14.7 −16.8 −38.2 −38.7 −31.0
NKIRAS2 Array 1.1 1.0 −1.3 −1.5 −1.9 −1.9 −1.8 −2.3
RT-PCR 1.4 −1.1 −1.4 −2.4 −4.1 −4.7 −5.9 −3.2
PTGS2 Array −2.1 −4.9 −6.4 −5.7 −3.3 −3.6 −3.1 −3.2
RT-PCR 1.0 −10.2 −26.1 −158.2 −39.8 −62.4 −72.7 −91.5
TNFAIP3 Array −1.5 −2.4 −4.0 −3.3 −3.1 −2.8 −2.7 −3.1
RT-PCR 1.6 −1.2 −2.9 −15.7 −9.7 −10.4 −10.5 −10.4
RNF25 Array 1.1 −1.2 −1.2 −1.3 −1.8 −1.5 −1.7 −2.4
RT-PCR 1.4 −1.2 −1.8 −4.7 −5.6 −8.1 −10.4 −17.8
TRAP1 Array 1.0 1.7 2.3 2.5 2.5 2.5 2.1 1.9
RT-PCR 10.0 14.0 31.4 1.7 52.6 35.4 26.4 18.0
KLF6 Array −1.1 −1.9 −2.7 −2.9 −2.4 −2.7 −2.5 −4.2
RT-PCR 1.1 −4.1 −5.6 −31.3 −14.5 −22.0 −32.3 −37.6
ELL2 Array −1.0 −1.3 −2.2 −3.2 −1.7 −2.5 −2.6 −2.8
RT-PCR 2.4 1.5 1.2 −3.7 1.3 −1.2 −1.9 −2.3
NR2F2 Array 1.6 2.5 2.0 1.4 1.2 −1.1 −1.3 −1.4
RT-PCR 1.5 3.7 2.6 −1.1 −1.2 1.0 −1.8 −2.7
PCNA Array 1.3 3.5 7.4 7.3 4.5 4.7 2.4 2.6
RT-PCR 1.2 4.2 5.0 3.8 3.5 2.7 2.8 2.1
DHFR Array 1.0 1.5 2.2 2.5 3.0 3.3 2.4 3.4
RT-PCR −1.2 3.4 7.2 9.8 11.9 10.8 13.5 16.1
CYR61 Array −1.0 −2.4 −5.3 −5.6 −5.8 −6.6 −5.6 −4.4
RT-PCR −1.6 −1.7 −3.2 −3.2 −3.6 −3.4 −2.2 −2.7
RGS4 Array 1.2 −1.5 −3.0 −3.7 −2.6 – – −2.4
RT-PCR 1.3 −2.2 −20.9 −34.5 −17.1 −17.4 −28.4 −26.2
FZD7 Array 1.8 2.1 2.0 2.8 1.4 1.4 1.0 1.3
RT-PCR 1.7 3.0 2.3 −1.8 1.3 1.2 1.1 −1.8
MDM2 Array 1.1 1.1 −1.6 −1.9 −1.8 −2.0 −2.9 −2.5
RT-PCR 1.7 1.1 −1.4 −1.8 1.4 1.0 −1.0 −2.1
WDR34 Array −1.8 −2.8 −3.0 −3.8 −4.1 −3.6 −4.2 −4.6
RT-PCR 1.6 2.5 6.0 2.7 8.8 9.2 5.2 5.0
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Table 5 (continued)
Symbol Assay 6 h 12 h 18 h 24 h 30 h 36 h 42 h 48 h
CFL2 Array 1.1 NA −1.2 1.3 2.4 4.2 3.0 2.1
RT-PCR −1.3 1.2 −1.8 −2.7 −1.9 −2.6 −1.8 −6.1
SERPINB2 Array 1.1 3.8 6.2 5.8 5.0 3.5 2.2 2.5
RT-PCR 1.8 −1.1 −9.3 −272.2 −188.3 −459.6 −434.5 −371.8
a and b as described in Table 1.
dQRT-PCR detection of the change (fold) of RNA expression in adenovirus-infected cells as compared to mock-infected cells.
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confluence. Cell phase was analyzed by using a modified
protocol for differential staining of DNA and RNA with
Hoechst 33342 and Pyronin Y (PY) (Shapiro, 1981). Briefly,
after fixation in 70% ethanol at 4 °C for 24 h, cells were re-
suspended in Hanks' balanced salt solution (HBSS) at a density
<2×106 cells/ml. After addition of the PY-Hoechst staining
solution, the samples were incubated for 20 min before
measuring the fluorescence by flow cytometry using a FACS
Vantage SE/DiVa (BD Biosciences).
Virus infection, nucleic acid extraction and protein preparation
Synchronized monolayer cells were mock-infected or
infected with Ad2 at a multiplicity of 100 fluorescence-forming
units (FFU) per cell (Philipson, 1961) in serum-free medium.
After 1 h adsorption at 37 °C, the medium was replaced with
MEM containing 10% FBS and incubated at 37 °C. Infected
cells were collected at 6, 12, 18, 24, 30, 36, 42, and 48 hpi.
Mock-infected cells were collected at 6 hpi. Total RNA was
extracted using TRIZOL Reagent (Invitrogen). The quantity and
quality of the RNA was assessed using the RNA 6000 Nano
LabChip kit and a Bioanalyzer 400 (Agilent Technologies).
DNA was isolated from cell pellets using the QIAamp DNA
Mini kit according to manufacturer's protocol (QIAGEN).
Protein samples were prepared by lysing the cell pellet with a
lysis buffer (1% SDS, 50 mMTris, pH 7.4, 150mMNaCl, 2 mM
EDTA, 2 nMPepstatin A, 10 nMAprotinin, 2 nMLenpeptin and
100 nM PMSF). After 5 min of centrifugation at 13,000 rpm, the
supernatant was collected.Fig. 4. Western blot analysis of the expression of SMAD proteins. Adenovirus-
infected cells were harvested at 6, 18, 30 and 42 hpi, and mock-infected cells
were harvested at 6 hpi (M). Total cellular proteins were extracted. Expression of
SMAD proteins was analyzed byWestern blot using polyclonal antibody against
SMAD4 and monoclonal antibody against SMAD1/2/3 as described in Material
and methods. Expression of β-actin (ACTN) was used as an internal control.Preparation of cDNA probes and microarray hybridization
Microarrays with approximately 29,800 human cDNA clones
were obtained from the Microarray Resource Center at the Royal
Institute of Technology (KTH), Sweden.2 The labeling and
hybridization were performed according to the CyScribe Post-
Labeling protocol (GEHealthcare). For each experiment, 10μg of
total RNA from mock- and adenovirus-infected cells was reverse
transcribed to generate amino allyl-modified cDNA, which was
coupledwith either Cy5 or Cy3NHS-dye esters, respectively. The
arrays were prehybridized in 5× SSC, 5× Denhardt's solution,
0.2 mg/ml tRNA, 0.5% SDS, and 50% formamide at 42 °C for
30 min, rinsed once with distilled H2O and once with 2-propanol,
followed by spin drying. After loading of the purified and pooled
cDNA probes, hybridization was performed in a dark humid
chamber at 42 °C overnight. After stepwise washing, the array
was dried by centrifugation. Each RNA sample was analyzed on
two arrays, one of which was “dye-swap” labeled.
Data collection, normalization and analysis
Array images were acquired at 10 μm resolution using a
GenePix 4000B Microarray scanner (Axon Instruments, Inc.)
and processed using the GenePix Pro 5.1 software. As a first
step, individual spots were identified using the irregular features
segmentation method and automatically classified according to
a flagging system (Axon Instruments). After measuring the
signal intensities in each spot, a second flagging was performed
to mark highly irregular spots with a circularity value ≤60 and
small spots with ≤45 foreground pixels. The data, including
corresponding images, were stored in the BASE database (Saal
et al., 2002) at the Linnaeus Centre for Bioinformatics (LCB), 3
Uppsala University. Data handling and normalization were
performed within the framework of LCB's Data warehouse. For
each experiment, intensity-dependent normalization was per-
formed at print-tip level (Yang et al., 2002).
To identify differentially expressed genes across the time
course, the normalized data were first exported and negatively
flagged values excluded. Spots exhibiting less than 50% missing
values were kept for significance analysis with the EDGE
(extraction of differential gene expression) software (Leek et al.,
2006; Storey et al., 2005). Differentially expressed genes were
then identified as significant at a 1% false-discovery rate in
conjunction with the additional requirement of an average fold
change≥2 in at least one of the time points. Using the same fold2 www.biotech.kth.se/molbio/microarray/.
3 www.lcb.uu.se.
Table 6
E2F-targeted genes
Clone ID Symbol 6 h 12 h 18 h 24 h 30 h 36 h 42 h 48 h Name
789182 PCNA c 1.3b 3.5 7.4 7.3 4.5 4.7 2.4 2.6 Proliferating cell nuclear antigen
453107 CDC45L – a 2.2 3.6 5.9 3.7 4.0 6.4 6.0 CDC45 cell division cycle 45-like (S. cerevisiae)
450711 CHAF1A – 2.9 4.1 3.9 4.1 2.9 3.3 4.0 Chromatin assembly factor 1, subunit A (p150)
346257 MCM4 – 2.6 2.9 3.6 3.3 4.1 2.9 5.0 MCM4 minichromosome maintenance deficient 4
1587847 MCM6 – 2.1 3.2 3.1 3.3 3.3 2.8 3.5 MCM6 minichromosome maintenance deficient 6
809557 MCM3 – 2.1 3.4 2.7 2.7 3.4 – 2.1 MCM3 minichromosome maintenance deficient 3
700721 MCM5 – 3.7 5.8 7.0 5.5 5.4 5.6 7.6 MCM5 minichromosome maintenance deficient 5,
cell division cycle 46
451907 ZWINT – – 3.3 6.4 5.2 4.1 4.5 6.3 ZW10 interactor
204214 CDC6 – – 4.0 4.9 2.7 3.9 – – CDC6 cell division cycle 6 homolog (S. cerevisiae)
826273 CCNE2 – – 4.0 4.0 2.2 2.3 2.3 2.5 Cyclin E2
842973 PA2G4 1.1 1.8 2.3 2.8 3.0 3.3 2.8 2.7 Proliferation-associated 2G4, 38 kDa
204301 CDC25A – – 3.8 3.2 2.1 3.5 – – Cell division cycle 25A
950690 CCNA2 – 1.5 2.4 3.1 1.9 1.3 – – Cyclin A2
68950 CCNE1 c – – 2.5 2.3 – – – – Cyclin E1
770992 EZH2 – 1.7 3.2 3.9 2.9 2.6 2.5 3.2 Enhancer of zeste homolog 2 (Drosophila)
768172 DHFR c 1.0 1.5 2.2 2.5 3.0 3.3 2.4 3.4 Dihydrofolate reductase
47384 MTHFD1 −1.0 1.8 2.9 3.4 3.3 3.4 3.4 3.4 Methylenetetrahydrofolate dehydrogenase
(NADP+-dependent) 1
379920 TK1 1.2 – 2.1 2.8 3.6 3.0 2.7 2.7 Thymidine kinase 1, soluble
624627 RRM2 −1.1 1.3 2.1 2.8 2.8 3.2 2.4 1.8 Ribonucleotide reductase M2 polypeptide
309288 RFC4 1.1 1.5 2.3 2.5 1.9 2.0 1.6 2.1 Replication factor C (activator 1) 4, 37 kDa
256260 RFC3 – 1.7 2.4 2.4 1.7 2.3 – 1.4 Replication factor C (activator 1) 3, 38 kDa
503097 PRPS2 −1.1 1.3 2.2 2.4 1.9 2.4 2.0 2.4 Phosphoribosyl pyrophosphate synthetase 2
712378 PKIA 1.0 1.4 2.1 2.0 1.8 1.8 1.4 1.4 Protein kinase (cAMP-dependent, catalytic) inhibitor alpha
897997 SMC1L1 1.1 1.7 2.0 2.3 2.3 2.3 1.6 2.3 SMC1 structural maintenance of chromosomes
1-like 1 (yeast)
323989 TFDP1 1.1 1.3 1.7 2.2 2.2 2.9 2.1 2.6 Transcription factor Dp-1
359119 CKS2 1.1 1.3 1.7 2.1 2.2 1.4 – 1.3 CDC28 protein kinase regulatory subunit 2
246304 BTG3 −1.1 −1.2 1.9 2.2 2.6 2.8 2.1 2.4 BTG family, member 3
2018976 PTTG1 1.1 1.2 1.5 2.3 3.2 2.2 2.8 4.0 Pituitary tumor-transforming 1
856289 CCNB2 – – 1.7 3.4 4.0 2.2 – 3.6 Cyclin B2
1476065 STMN1 −1.0 −1.0 1.7 2.2 3.1 3.4 2.6 2.8 Stathmin 1/oncoprotein 18
882510 KPNA2 −1.0 1.2 1.5 2.2 2.2 2.1 1.1 −1.4 Karyopherin alpha 2 (RAG cohort 1, importin alpha 1)
825470 TOP2A −1.1 1.0 1.7 2.1 1.8 1.6 1.4 1.8 Topoisomerase (DNA) II alpha 170 kDa
856796 SRM 1.3 2.0 1.5 1.5 1.5 1.3 1.1 −1.4 Spermidine synthase
1534399 BRD2 1.1 2.3 1.7 1.2 −1.3 −1.6 −1.9 −2.2 Bromodomain containing 2
756405 ID3 1.6 2.1 1.0 −1.3 −1.8 −1.9 −2.2 −3.2 Inhibitor of DNA binding 3, dominant negative
helix–loop–helix protein
a, b and c as described in Table 1.
Table 7
Transiently up-regulated cellular genes at 12 hpi
Clone ID Symbol 6 h 12 h 18 h 24 h 30 h 36 h 42 h 48 h Name
853938 DYNLL1 1.6b 2.1 1.2 −1.0 −1.4 −1.6 −2.0 −2.1 Dynein, light chain, LC8-type 1
245990 MT1F 1.2 2.1 1.2 −1.1 −1.6 −1.9 −1.9 −1.6 Metallothionein 1F (functional)
1472735 MT2A 1.3 2.1 1.1 −1.2 −1.8 −2.4 −2.6 −2.2 Metallothionein 2A
825461 GADD45B 1.6 2.4 −1.6 −1.6 −2.4 −2.1 −1.5 −1.6 Growth arrest and DNA-damage-inducible, beta
153646 COL1A1 1.0 2.0 1.6 1.1 −1.4 −1.8 −2.8 −3.8 Collagen, type I, alpha 1
1589973 BOLA3 1.2 2.1 2.0 2.1 1.9 1.4 – a 1.5 BolA-like 3 (E. coli)
796284 IRS1 1.0 2.3 1.9 1.8 1.3 1.1 1.3 1.1 Insulin receptor substrate 1
1534399 BRD2 1.1 2.3 1.7 1.2 −1.3 −1.6 −1.9 −2.2 Bromodomain containing 2
756405 ID3 1.6 2.1 1.0 −1.3 −1.8 −1.9 −2.2 −3.2 Inhibitor of DNA binding 3, dominant negative
helix–loop–helix protein
434768 FST 1.3 2.2 −1.5 −1.9 −2.7 −2.4 −3.2 −3.8 Follistatin
856796 SRM 1.3 2.0 1.5 1.5 1.5 1.3 1.1 −1.4 Spermidine synthase
756709 USP8 – 2.3 2.0 1.5 1.5 1.4 – −1.1 Ubiquitin-specific peptidase 8
377384 NR2F2c 1.6 2.5 2.0 1.4 1.2 −1.1 −1.3 −1.4 Nuclear receptor subfamily 2, group F, member 2
32854 ARSJ 1.3 2.7 1.2 −1.2 −1.3 −1.5 −1.8 −1.9 Arylsulfatase family, member J
296679 Unnamed 1.3 2.1 1.1 −1.1 −1.4 −1.9 −1.9 −1.6
202535 Unnamed 1.3 2.4 1.2 −1.2 −1.6 −2.2 −2.4 −2.1
a, b and c as described in Table 1.
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373H. Zhao et al. / Virology 363 (2007) 357–375criteria, a complementary selectionwas also performed at the first
four time points among genes with a coefficient of variation (CV)
less than 50%. The datasets were combined and the individual
genes were sorted according to time points of significant
expression changes. For visualization of the data, the Genesis
1.6.0 software was used to generate a heat map which depicts all
expression changes larger than 2-fold (Sturn et al., 2002).
Quantitative real-time PCR analysis (QRT-PCR)
QRT-PCR assays were used to (i) determine the progression
of the virus infection by monitoring the expression of E1A and
CCNE1, as well as the replication of viral DNA and (ii) verify
the results obtained from the microarray experiments. For the
verification of microarray results, the QRT-PCR analyses were
performed on the same sets of RNA samples as used for the
microarray hybridizations. All QRT-PCR analysis were per-
formed using SYBR green, except for the analysis of CCNE1,
SMURF2, JUN, MYC, CFL2 and CYR61 expression, which
were done using TaqMan MGB probes from Applied Biosys-
tems. QRT-PCR primers were designed using Primer Express
(Applied Biosystems). The list of primers and sequences is
included in the supplementary material. To generate cDNA, 2 μg
of total RNAwas reverse transcribed in a total reaction mixture
of 20 μl using the Omniscript RT kit according to the
manufacturer's protocol (Qiagen). The QRT-PCR analyses
were carried out on an ABI PRISM 7700 HT sequence detection
system (Applied Biosystems) using either SYBR green detection
or TaqMan probes as previously described (Zhao et al., 2003).
Western blot analysis
The cell lysate, containing 20 μg protein, was mixed with 2×
Laemmli sample buffer (62.5 mM Tris–HCl, pH 6.8, 25%
glycerol, 0.01% BFB and 2% SDS), boiled for 5 min and then
loaded on a 10% SDS–polyacrylamide gel. After electrophor-
esis, the proteins were transferred to a polyvinylidene difluoride
membrane in a blotting chamber (GE Healthcare). The
membrane was blocked for 1 h at room temperature in ECL
blocking agent (GE Healthcare). The membranes were
incubated with the primary antibodies for 1 h at room
temperature. Membranes were washed three times for 10 min
in Tris-buffered saline with 0.05% Tween-20 (TBS-T) before
the secondary antibody was added. After 1 h of incubation at
room temperature, the membranes were washed four times for
10 min in TBS-T. To detect signals on the membranes, an ECL
kit (GE Healthcare) was used. Film (Kodax) was exposed and
developed. Monoclonal antibodies against SMAD1/2/3 and
polyclonal antibody against SMAD4 and β-actin were obtained
from Santa Cruz Biotechnology.
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